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Chapter I 
Introduction 
1.1. Purpose 
The European Society for Vascular Surgery (ESVS), according to its mission, appointed the 
Vascular Access (VA) Writing  Committee (WC) to write the current clinical practice 
guidelines document for surgeons and physicians who are involved in the care of patients 
with HD and VA. The goal of these Guidelines is to summarize and evaluate all the current 
available evidence to assist physicians in selecting the best management strategies for all 
patients needing a VA or for pathologies derived by VA. However, each respective physician 
must make the ultimate decision regarding the particular care of  an individual patient.(1, 2) 
Patients with VA for HD are complex and are subject to significant clinical practice variability, 
although a valid evidence base is available to guide recommendations. The significant 
technical and medical advances in VA have enabled guidelines to be proposed with greater 
supporting evidence than previously. Potential increases in health care costs and risks due to 
the industry- and public-driven use of novel treatment options makes the current guidelines 
increasingly important. (3-6) 
Many clinical situations involving patients with HD and VA have not been subjected to 
randomised clinical trials. Nevertheless, patient care must be delivered and clinical decisions 
made in these situations. Therefore, this document should also provide guidance, when 
extensive level I evidence is unavailable and, in these situations, recommendations are 
determined on the basis of the best currently available evidence. 
By providing information on the relevance and validity of the quality of evidence, the 
reader will be able to gather the most important and evidence-based information relevant to 
the individual patient.  
This document is intended to be a guide, rather than a document of rules, allowing flexibility 
for specific patients' circumstances. The resulting clinical practice guidelines document 
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provides recommendations for the clinical care of patients with HD and VA including 
preoperative, perioperative and postoperative care and long-term maintenance. 
 
1.2. Methodology 
The VA WC  was formed by members of ESVS and VAS (Vascular Access Society) from 
different European countries, various academic and private hospitals and by vascular 
surgeons, nephrologists, radiologists and clinical nurses in order to maximize the applicability 
of the final guideline document. The VA Guideline WC met in September 2012 for the first 
time to discuss the purpose, contents, methodology and timeline of the following 
recommendations. 
The VA WC has performed a systematic literature search in MEDLINE, EMBASE and 
COCHRANE Library databases for each of the different topics that are discussed and 
reviewed in this guidelines document. The latest literature search was performed in 
November 2015. With regard to evidence gathered, the following eligibility criteria have been 
applied: 
 Only peer-reviewed published literature has been considered 
 Published abstracts or congress proceedings have been excluded 
 Randomized clinical trials (RCT) as well as meta-analyses and systematic 
reviews were searched with priority 
 Non-randomized clinical trials and non-controlled trials were included 
 Well-conducted observational studies (cohort and case-control studies) were 
also included 
 Previous guidelines, position papers and published consensus documents have 
also been included as part of the review process when new evidence was 
absent 
 Minimizing the use of reports from a single medical device or from 
pharmaceutical companies reduced risk of bias across studies. 
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A grading system based on the European Society of Cardiology (ESC) guidelines 
methodology was adopted.(7) The level of evidence classification provides information about 
the study characteristics supporting the recommendation and expert consensus, according 
the categories shown in Table 1.   
 
Table 1 : Levels of evidence (7) 
 
 
The recommendation grade indicates the strength of a recommendation. Definitions of 
the classes of recommendation are shown in Table 2. 
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Table 2 : Grades of strength of recommendations according the ESC grading system 
(7) 
 
 
For each recommendation, two members of the WC assessed the strength of a 
recommendation and the quality of supporting evidence independently. A full master 
copy of the manuscript with all recommendations was electronically circulated and 
approved by all WC members. Recommendations that required consensus were 
discussed and voted upon meetings and by e-mailing among all members of the WC. 
This system permits strong recommendations supported by low or very low-quality 
evidence from downgraded RCTs or observational studies only when a general 
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consensus among the WC members and reviewers is achieved. 
Two members of the WC have prepared each part of the guidelines document. An 
internal review process was performed before the manuscript was sent to independent 
external reviewers. External reviewers made critical suggestions, comments and 
corrections on all preliminary versions of this guideline. In addition, each member 
participated in the consensus process concerning conflicting recommendations. The 
final document has been approved by the ESVS Guidelines Committee and submitted 
to the European Journal of Vascular and Endovascular Surgery (EJVES). Further 
updated guidelines documents on VA will be provided periodically by the ESVS when new 
evidence and/or new clinical practice arise in this field, which could occur every four years. 
To optimize the implementation of the current document, the length of the guidelines 
has been kept as short as possible to facilitate access to guideline information. This 
clinical guidelines document was constructed as a guide, not a document of rules, 
allowing for flexibility with various patient presentations. The resulting clinical practice 
guidelines provide recommendations for the clinical care of patients with VA including 
preoperative, perioperative and post-operative care. 
Conflicts of interest from each WC member were collected prior to the writing process. 
These conflicts were assessed and accepted by each member of the WC and are 
reported in this document. In addition, the WC agreed that all intellectual work should 
be expressed without any interference beyond the honesty and professionalism of all 
members and assistants during the writing process. 
 
 
1.3. Definitions 
1.3.1. Definition of vascular access 
Patients with acute renal failure or end stage renal disease require renal replacement 
therapy by peritoneal dialysis (PD), hemodialysis (HD) or kidney transplantation (Figure 1). 
VA is essential for patients on HD and can be accomplished either using central venous 
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catheters (CVC), or by arterialization of a vein or interposing of graft between an artery and a 
vein for the insertion of HD needles. The blood flow available for HD should reach at least 
300ml/min and preferably to 500ml/min depending on the access modality to allow a 
sufficient HD.           
 
Fig. 1 Renal replacement therapy 
 
1.3.2. Other definitions 
Arteriovenous fistulas (AVF) and arteriovenous grafts (AVG) are established terms to 
characterize  a special kind of VA in patients on HD. We define an autogenous anastomosis 
between an artery and a vein as an arteriovenous fistula and an access using a prosthetic 
graft as arteriovenous grafts.  
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At the beginning of this millennium interventional radiologists and vascular surgeons 
attempted to clarify the terminology dealing with HD access.(8-10) Some of these definitions 
have been revised and (11) further refinements made; there is still ongoing discussion 
amongst VA specialists. Nevertheless we have outlined below the definitions that we believe 
to be currently accepted by the majority of clinicians in the field.  
 
Table 3: Classification of chronic kidney disease based on glomerular filtration rate 
(GFR) (8-11) 
 
Stage Description GFR 
mL/ Min / 1.73 m
2
 
Stage 1 Kidney damage with normal or elevated GFR 90+ 
Stage 2 Kidney damage with mildly decreased GFR 60-89 
Stage 3 Moderately decreased GFR 30-59 
Stage 4 Severely decreased GFR 15-29 
Stage 5  End-stage kidney failure (ESRD) < 15 or on dialysis 
 
Incidence is the proportion of a given population developing a new condition or experiencing 
an event within a specified period of time. This could be i.e. the number of patients 
experiencing an event (e.g. patients undergoing vascular access creation) divided by the 
number of a given population (e.g. the number of patients undergoing HD). For a disease 
incidence can be expressed as number of patients per million population per year.  
 
Prevalence is the total number of cases of a disease within a given population; it 
encompasses both new and continuing patients with a certain disease and is expressed as 
patients per million population. Prevalence is a function of incidence (new cases) and 
outcomes (death or cure).  
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Point prevalence in %: Number of patients using a specific type VA at a given point of time 
divided by the number of patients with a VA at this time multiplied by 100.      
 
Period prevalence in %: The mean number of patients using a specific VA over a given time 
(one year) divided by all the number of patients using a VA during the same time period 
multiplied by 100.  
 
Hospitalisation days/1000 access days:  The numerator is the total number of days of 
hospitalization for the study population. The denominator is calculated as the number of days 
from access creation or the start date of a study period to permanent (unsalvageable) access 
failure, the end of study period, death of the patient, transfer from the dialysis unit or  a 
change in modality of renal replacement (peritoneal dialysis or transplantation). The 
calculated rate is the total number of hospitalization days ⁄ total number of access days  
multiplied by 1000 to achieve the number of hospitalization days/1000 access days. 
 
Access abandonment: The day on which an access is deemed to be permanently unusable 
or unavailable for cannulation. 
 
Primary VA: Creation of a functioning VA for the first time. It can be reported using a 
standard time to event analysis (Kaplan-Meier) or specific time points (30 days, 6 month, one 
year/ two years). 
 
Secondary VA: VA creation after a failed VA. 
 
Tertiary VA: VA using GSV or FV translocated to the arm or leg. Unusual access procedures 
such as upper or lower limb arterio-arterial loops are included in this category 
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Transposition: Relocation of an autogenous vein to a new (more superficial) position in the 
soft tissues of the same anatomical area (e.g. an upper arm AVF with transposition of the 
basilic vein). 
 
Translocation: The prepared vein is completely disconnected and inserted in a new 
anatomical area to create an AVF. 
 
Superficialization: the index vein is elevated in the subcutaneous tissue without any 
detaching or rerouting the vein. 
 
Kaplan-Meier life-table: A statistical method for calculating time-dependent clinical outcomes 
can be documented such as access patencies, time to thrombosis or infection free survival. 
 
Primary patency: The interval between VA creation and the first re-intervention (intervention-
free access survival) for access dysfunction or thrombosis or the time of measurement of 
patency   
 
Assisted primary patency: Interval between VA creation and the first occlusion (thrombosis-
free access survival) or measurement of patency including operative/endovascular 
interventions to maintain the VA. 
 
Primary functional patency: Interval between the first use (first cannulation) of new created 
VA and the first re-intervention to rescue the VA. 
 
Secondary patency: Interval between VA creation and the abandonment of this VA (i.e. 
thrombosis) after one or more interventions or achievement of a censored event (death, 
change of HD modality, loss for follow-up). This can be documented graphically as 
cumulative survival curve. 
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Maturation of VA: Changes that occur in the VA after its creation (increase in access flow 
and AVF diameter, wall structure changes, AVG tissue-to-graft incorporation) making the 
access to become over time suitable for cannulation. 
 
Mature VA: A VA that is expected to be suitable for HD access and considered appropriate 
for cannulation with two needles and expected to deliver sufficient blood flow throughout the 
HD. Therefore it is a pre-cannulation definition. 
 
Adequate VA: A VA is adequate, appropriate or suitable for HD when it has been cannulated 
successfully with two needles, over a period of at least 6 HD sessions during a 30-day 
period, and delivering the prescribed blood flow throughout the HD and achieves adequate 
HD (usually at least 300 ml/ min). Therefore it is a post-cannulation definition. 
 
Functional VA: A VA that is currently being used for HD access.  
 
Monitoring: Examination and evaluation of the VA by means of physical examination to 
detect physical signs that suggest the presence of access dysfunction 
 
Surveillance:  Periodic evaluation of a VA by using hemodynamic tests. This may trigger 
further diagnostic evaluation.  
 
VA induced (limb) ischaemia: Upper extremity malperfusion after VA creation can be 
classified in four stages: 
stage 1: slight coldness, numbness, pale skin, no pain 
stage 2: loss of sensitivity, pain during HD or exercise 
grade 3: rest pain 
grade 4: digital tissue loss    
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The definition is more appropriate then ‘steal’ which describes the physiological phenomena 
of a (even retrograde) blood flow recruitment towards the AVF/AVG. 
 
Recirculation: The return of dialyzed blood to the systemic circulation without full equilibration  
(NKF-DOQI guidelines) 
 
Kt/V: A parameter to quantify the adequacy of the HD  : K = Dialyzer clearance of urea, t = 
effective time of HD  V =  volume of urea distribution , approx. equal to patient’s body water 
(60% of the body mass).   
 
Early VA failure: A VA that has occluded within 24 hours of creation.  
 
Early dialysis suitability failure: A VA that cannot be used by the third month following 
creation despite radiological or surgical intervention.  
 
Late dialysis suitability failure: A VA that is not usable after more than 6 months despite 
radiological or surgical intervention.  
 
Cannulation failure: Failure is defined as the inability to place and secure two dialysis 
needles.  
 
Non-tunneled CVC: An uncuffed catheter providing temporary VA for HD.  
 
Tunneled CVC: A subcutaneously tunneled dual-lumen catheter with a cuff that can be used 
for VA if HD is expected to last for more than two weeks. 
 
Catheter related bacteremia:  
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Definite: Bacteremia with at least one positive percutaneous peripheral vein blood culture 
and where either the same pathogen was cultured from the catheter tip or a blood culture 
drawn from a catheter that has a > 3 fold greater bacterial colony count than those drawn 
from a peripheral vein.  
Likely: Bacteremia with positive blood cultures obtained from a catheter and/or peripheral 
vein in a patient where there is no clinical evidence for an alternative source of an infection. 
 
Catheter exit site infection:   
Proven: The presence of a purulent discharge or erythema, induration/and or tenderness at 
catheter exit site with a positive bacteriological culture of serious discharge.  
Probable: The clinical signs of infection with negative cultures from the discharge or blood 
without signs of irritation from gauze, stitches or the cleansing agent. 
 
Catheter tunnel infection: 
Proven: The presence of purulent discharge from tunnel or erythema, induration and/or 
tenderness over the catheter tunnel with a positive culture.  
Probable: Clinical signs of infection around the catheter site with negative cultures from the 
discharge or blood. 
 
Primary catheter site patency: Interval between catheter insertion and the first intervention to 
save the catheter’s function.  
 
Secondary catheter site patency: Interval between catheter insertion and exchange or 
removal of the catheter for any reason. 
 
Continuous catheter site: The time period from initial catheter insertion to catheter site 
abandonment for any reason including the time period after continuous catheter exchanges 
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in the same target vessel. The time period and number of exchanges are documented e.g. 
12 months [3 catheters]. 
 
Catheter dysfunction: This is the first occurrence of either a peak flow of 200 ml/minute or 
less for 30 minutes during HD, a mean blood flow of 250 ml/minute or less during two 
consecutive dialyses or the inability to initiate HD resulting from an inadequate blood flow, 
despite attempts to restore patency.   
 
Chapter II 
 
Epidemiology of chronic kidney disease (CKD) Stage 5 
2.1. Epidemiology of chronic kidney disease 
Chronic kidney disease (CKD) is a worldwide public health problem. CKD is defined as 
kidney damage or glomerular filtration rate (GFR) below 60 ml/min per 1.73 m2 for 3 months 
or more irrespective of the cause. CKD is classified into five stages (Table 3).(12)  
The true incidence and prevalence of CKD within a community are difficult to ascertain as 
early to moderate CKD is usually asymptomatic. Most studies point to a prevalence of CKD 
of around 10%, albuminuria of around 7%, and GFR below 60 ml/min per 1.73 m2 of around 
3%.(13-15) 
CKD stage 5 (ESRD) is characterized by GFR below 15 ml/min per 1.73 m2 and includes two 
phases: the first one is treated conservatively without dialysis; when the second phase 
follows, the initiation of  renal replacement therapy (RRT) in the form of dialysis or 
transplantation is required to sustain life. 
Incidence of CKD stage 5 refers to the number of patients with ESRD beginning RRT, thus 
failing to take into account patients not treated by RRT and underestimating the overall true 
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incidence of ESRD.  In the dialysis population, prevalence is a function of the incidence (new 
cases) and outcome (transplantation or death) rates of ESRD. 
2.1.1. Epidemiology of end stage renal disease 
2.1.1.1. Incidence 
The number of patients per year starting RRT has shown an exponential rise. (16) Such a 
large number of CKD patients requiring dialysis may have three main causes: patient 
selection, competitive risks and true increase in CKD incidence: 
1. Selection of patients for RRT: the steep increase in the incidence of older patients 
suggests that those very old and/or those affected by particularly severe comorbidities did 
not get access to dialysis in the first decades of RRT, compared to the more recent years.  
2. Competitive risks: a very recent study suggested that the number of deaths where CKD is 
the underlying cause of death increased by 82% from 1990 (27th in the global death rank) to 
2010 (18th in the global death rank).(17) A high risk of death exists even in patients in the 
early stages of CKD, with many individuals in stages 3 and 4 dying before starting RRT.(18, 
19) In fact, a reduced GFR is considered as one of the most important risk factors for 
coronary heart disease.(20) Substantial improvements in the treatment of cardiac diseases 
and in survival have occurred in the last decades and this has allowed many patients to 
survive in the more advanced CKD stages and to require RRT. 
3. True increase in CKD incidence: it may also be possible that the increased incidence of 
ESRD reflects increases in the underlying prevalence of CKD. The Framingham Heart Study 
has shown that the incidence of type 2 diabetes has doubled from the 1970s to the 
1990s.(21) Furthermore, potentially nephrotoxic drugs, such as non-steroidal anti-
inflammatory drugs, antibiotics and chemotherapy agents are more commonly used.  
 
 
 
 
25 
 
 
2.1.1.2. Prevalence 
Data related to the prevalence of CKD stage 5 are lacking, except for those of registries of 
ESRD patients treated by dialysis or transplantation. In the USA, of the 547,982 prevalent 
ESRD patients in 2008, 70 percent were being treated with dialysis while 30 percent had a 
functioning graft. In 2008 alone, 112,476 patients entered the US ESRD program. Adjusted 
rates for incident and prevalent ESRD are 351 and 1,699 cases per million population, 
respectively. Diabetes and hypertension account for 44 and 27.9 per cent of all causes of 
incident ESRD, respectively.(22) 
The prevalence of a disease increases if the survival of the patient increases with a constant 
incidence rate or if the incidence rate increases with a constant survival rate. The rising 
prevalence of treated ESRD can be attributed to the increase in the number of patients who 
start RRT each year and/or to increased survival of patients with ESRD. Since the incidence 
rates of treated ESRD have flattened in recent years, longer lifespans of prevalent ESRD 
patients may partially explain the steady growth of this population.(22) Continuing global 
efforts should be made in the prevention and treatment of acute and especially chronic 
conditions potentially leading to ESRD, in particular diabetes and hypertension.  
2.2. Demographics of end stage renal disease 
The global epidemiology of ESRD is heterogeneous and influenced by several factors. 
Consequently, the incidence and prevalence of ESRD are markedly different from country to 
country (Table 4). Disparities in the incidence and prevalence of ESRD within and between 
developed countries reflect racial and ethnic diversities as well as their impact on the 
prevalence of diabetes and hypertension in respective countries and communities. The 
incidence is higher among African and Native Americans and aboriginals of Australia and 
New Zealand.(12, 22-26) Diabetes as cause of ESRD is particularly frequent in these 
populations. Disparities with developing countries are likely to reflect availability of and 
access to RRT in low and middle income economies rather than a lower incidence of CKD. 
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Diabetes as the primary cause of CKD affects a particularly high percentage of incident 
patients in the USA.  
The elderly are a substantial and growing fraction of the RRT population worldwide, reaching 
25-30% in most ESRD registries.(22, 24)  In the United States, the proportion of patients > 
65 years of age starting dialysis has increased by nearly 10% annually, representing an 
overall increase of 57% between 1996 and 2003.(22) In Canada, from 1990 until 2001, the 
incident dialysis rate among patients aged 75 and older increased 74%.(25) Researchers 
have speculated that more liberal acceptance of the very elderly (> 80 years) into dialysis 
programs has contributed to the increase in patients with ESRD(27, 28).  
CKD is expected to be a major 21st century medical challenge. In developing nations, the 
growing prevalence of CKD has severe implications on health and economic output.(29) The 
rapid rise of common risk factors such as diabetes, hypertension and obesity, especially 
among the poor, will result in even greater and more profound burdens that developing 
nations are not equipped to handle.(29) 
Table 4. Global incidence and prevalence of RRT (per million population) in different parts of 
the world in 2002 and 2006.  
 Incidence Prevalence 
 2002 2006 2002 2006 
UNITED STATES 333 360 1,446 1,626 
Caucasians 255 279 1,060 1,194 
African Americans 982 1,010 4,467 5,004 
Native Americans 514 489 2,569 2,691 
Asians 344 388 1,571 1,831 
Hispanics 481 481 1,991 1,991 
AUSTRALIA 94 115 658 778 
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Aboriginals, Torres Strait 393 441 1,904 2,070 
EUROPE 129 129 770 770 
United Kingdom 101 113 626 725 
France 123 140 898 957 
Germany 174 140 918 957 
Italy 142 133 864 1,010 
Spain 126 132 950 991 
JAPAN 262 275 1,726 1,956 
Source: References 20-23 
 
2.3. Epidemiology of vascular access for dialysis  
Large differences in VA exist between Europe, Canada, and the United States, even after 
adjustment for patient characteristics.(30) VA care is characterized by similar issues, but with 
a different magnitude. Obesity, type 2 diabetes, and peripheral vascular disease, 
independent predictors of CVC use, are growing problems globally, which could lead to more 
difficulties in native arteriovenous fistula placement and survival. 
Nevertheless, in the USA following the establishment of the Fistula First Initiative, AVF use 
among prevalent HD patients increased steadily from 34.1% in December 2003 to 60.6% in 
April 2012.(31) In incident patients, VA statistics at the start of chronic HD in 2009 were the 
following: AVF in use 14.3%; AVG in use 3.2%; CVC in use 81.8%; AVF maturing 15.8%; 
AVG maturing 1.9%. 
International data from DOPPS has shown large variations in VA practice(32) and greater 
mortality risks have been seen for HD patients dialyzing with a catheter, while patients with 
usable AVF have the lowest risk.(33) International trends in VA practices have been 
observed within the DOPPS Study from 1996 to 2007.(32) Between 2005 and 2007, a native 
AVF was used by 67–91% of prevalent patients in Japan, Italy, Germany, France, Spain, the 
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UK, Australia and New Zealand, and 50–59% in Belgium, Sweden and Canada. From 1996 
to 2007, AVF use rose from 24% to 47% in the USA but declined in Italy, Germany and 
Spain. Across three phases of data collection, patients consistently were less likely to use an 
AVF versus other VA types if female, of older age, having greater body mass index, 
diabetes, and peripheral vascular disease. In addition, countries with a greater prevalence of 
diabetes in HD patients had a significantly lower percentage of patients using an AVF. 
Despite poorer outcomes for CVC, catheter use rose 1.5- to 3-fold among prevalent patients 
in many countries from 1996 to 2007, even among non-diabetic patients 18–70 years old. 
Furthermore, 58–73% of incident patients used a CVC for the initiation of dialysis in five 
countries despite 60–79% of patients having been seen by a nephrologist more than 4 
months prior to ESRD. The median time from referral until access creation varied from 5–6 
days in Italy, Japan and Germany to 40–43 days in the UK and Canada. Surgery waiting 
time, along with time from access creation until first cannulation, significantly affected the 
possibility of starting HD with a permanent access. (32) 
Surprisingly, patient preference for a CVC also varied across countries, ranging from 1% of 
HD patients in Japan and 18% in the United States, to 42% to 44% in Belgium and 
Canada.(34) Preference for a CVC was positively associated with age, female sex, and 
former or current catheter use. The observed considerable variation in patient preference for 
VA suggests that patient preference may be influenced by sociocultural factors and thus 
could be modifiable. 
The use of CVCs carries a significant risk for serious complications. Lately, in non-renal 
patients the peripherally inserted central venous catheter (PICC) has gained in popularity 
due to presumed advantages over other CVC.  
Early referral of ESRD patients to the nephrologist is strongly recommended. This approach 
may minimize the use of catheters and reduce catheter-related morbidity and need for 
hospitalization.(35) Early referral to the nephrologist is also required for psychological 
preparation for dialysis, discussion of for dialysis modality options, interventions to delay 
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progression of renal damage and to correct hypertension, anemia and metabolic effects of 
renal failure.(36) Time from referral to surgery for AV access creation should also be as short 
as possible.(32) 
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CHAPTER III 
Clinical Decision Making 
3.1. Choice of vascular access 
Successful HD treatment is only possible with a well-functioning VA. The ideal vascular 
access should allow cannulation using two needles, deliver a minimal blood flow of at least 
300 ml/min through the artificial kidney, is resistant to infection and thrombosis and have 
minimal adverse events. The first option for the construction of a VA is the creation of an 
autogenous arteriovenous fistula (AVF). Secondary and tertiary options are prosthetic 
arteriovenous grafts (AVG) and CVCs.  The reason to create autogenous AVFs is that 
observational studies show a lower incidence of postoperative complications and fewer 
endovascular and surgical revisions for AVF failure in comparison to AVGs.(37) In addition, 
the use of CVCs results in a significantly higher morbidity and mortality rate. The 
hospitalization risk for access-related reasons and particularly for infection is highest for 
patients on HD with a catheter at initiation and throughout follow-up.(38) The principle of 
venous preservation dictates that the most distal AV fistula possible should usually be 
performed.(39) 
The strategy is to start HD in incident patients with a distal autogenous AVF preferentially in 
the nondominant upper extremity. In cases of a failed distal access a more proximally located 
AVF can be performed.  
 
3.2. Timing of referral for vascular access surgery 
Timely patient referral to the VA surgeon for access creation is of importance for the outcome 
of the access. Early referral results in more and well-functioning autogenous AVFs(40), while 
late referral results in a greater chance on AVF nonmaturation and the need for CVC for HD. 
(41-43) Also, HD initiation with a CVC and a long AVF maturation time, results in poorer 
long-term patency rates of AVFs. The same factors that predict worse primary AVF survival 
are also associated with greater risk of final failure. The presence of cardiovascular disease, 
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utilization of catheters at HD initiation, and early cannulation are independent predictors of 
final failure. A lower cut-off level of time to cannulation is associated with the greatest risk of 
final failure. (40) (Fig. 2 and 3) Frequent pre-nephrology visits (PNV) are related to improved 
patient survival during the first year after initiation of HD, indicating the possible survival 
benefit with increased attention to PNV, particularly for elderly and diabetic patients. (44, 45) 
From the DOPPS data, great differences between the European countries in referral type 
and time of access creation, have been reported. Planning of access surgery varies between 
< 5 days (Italy) to > 42 days (UK) after referral to the VA surgeon.(32) 
The knowledge and experience of the VA surgeon is of importance to create predominantly 
autogenous fistulas and has a major impact on the outcome of surgery.(46, 47) However, 
there remain large regional differences between hospitals, concerning the number of 
autogenous AVFs created and the chance on successful maturation.(48) 
 
 
 
Fig. 2. Kaplan-Meier curves of time to AVF failure (primary patency from first cannulation) by 
use of catheters (CVC) at the initiation of HD (left) and by the time to maturation in days 
(right).(40) 
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Fig. 3. Risk factors associated with primary and secondary access failure. 
Hazard ratios plotted using a logarithmic scale (cardiovascular disease=CVD).(40) 
 
3.3. Selection of modality of vascular access  
3.3.1. Primary option for vascular access - autogenous arteriovenous fistula 
The radial-cephalic AVF at the level of the wrist (RCAVF) is the first choice to create VA. 
When successfully matured, the RCAVF can function for years with a minimum of 
complications, revisions and hospital admissions. The RCAVF is preferentially created in the 
nondominant arm, but the dominant extremity may be chosen if the vessels in the 
nondominant arm are unsuitable. The indication to perform a wrist RCAVF depends on the 
outcome of physical examination (inspection and palpation of distal veins and arteries) and 
additional ultrasound examination. A minimal internal vessel diameter for both radial artery 
and cephalic vein of 2.0 mm (with proximal tourniquet) is considered to be adequate for 
successful fistula creation and maturation. For brachio-cephalic and brachial-basilic AVFs a 
minimal arterial and venous diameter of 3 mm would be sufficient. 
 
 
33 
 
Major disadvantages are the risk of early thrombosis and non-maturation and, ultimately, 
access failure. A meta-analysis showed a mean early failure percentage of 17%.(49) 
However recent studies have shown higher failure rates of up to 46% with one year 
patencies from 52 to 83% (Table 5). An elderly dialysis population with concurrent 
comorbidities and poor upper extremity vessels, resulting in more RCAVF failures, is the 
reason for these high early failure percentages.(50)  
When a wrist RCAVF is not possible or has failed, a more proximally located AVF in the 
forearm, antecubital region or upper arm may be performed. These accesses are called mid-
forearm, brachial /radial-deep perforating vein(51), brachial-median cubital vein, brachial-
cephalic (BCAVF) and brachial-basilic AVFs (BBAVF). Brachial artery-based AVFs deliver a 
high access flow which is favorable for high HD flows, but may result in low distal arterial 
perfusion and cardiac overload.(52) These types of AVFs have good one year patencies 
(Table 6 and 7) with a low incidence of thrombosis (0.2 events per patient/ year) and 
infections (2%).  
If direct arteriovenous anastomoses are impossible, vein transposition/translocation can be 
performed, with redirection of a suitable vein to an available artery (forearm radial/ulnar-
basilic AVF) or greater saphenous vein harvesting from the leg and subsequently 
implantation between an arm artery and vein (see Chapter VIII). 
A BVT in the upper arm is a good choice when RCAVFs or BCAVFs have failed. BBAVFs 
can be performed in either one or two-stage operations. 
 
 
 
 
 
 
Table 5.  Early failure and one-year secondary patency rate of radial-cephalic AVF 
Reference  No. RCAVF  Early failure (%) Secondary patency  (%) 
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Silva et al (53)   108 26 83 
Golledge et al (54)  107 18 69 
Wolowczyk et al (55)  208 20 65 
Gibson et al (56)  130 23 56 
Allon et al (57)  139 46 42 
Dixon et al  (58)  205 30 53 
Ravani et al (59)  197 5 71 
Rooijens et al (60)   86 41 52 
Biuckians et al (61)  80 37 63 
Huijbregts et al (50)  649 30 70 
 
 
Table 6.  Early failure (within one month of access creation) and one-year secondary 
patency rate of brachial-cephalic AVF (including brachial- cephalic/perforating vein 
AVF ) 
Reference  No.BCAVF  Early failure (%) Secondary patency (%) 
    
Murphy et al (62) 208 16 75 
Zeebregts et al (63)  100 11 79 
Lok et al (64)  186 9 78 
Woo et al (65) 71 12 66 
Koksoy et al (66)  50 8 87 
Palmes et al (67) 55 9 89 
Ayez et al (68) 87 8 83 
Table 7. Early failure (within one month of access creation) and one-year secondary 
patency rate of brachial-basilic AVF 
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Reference   No.BBAVF  Early failure (%) Secondary patency (%) 
     
Murphy et al (62)   74 3 75 
Segal et al (69)   99 23 64 
Wolford et al (70)   100 20 47 
Arroyo et al (71)  65 8 88 
Keuter et al (72)   52 2 89 
Koksoy et al (66)   50 8 88 
Field et al (73)  140 19 69 
Ayez et al (68)  86 6 73 
 
3.3.1.1. Patient variables and outcome of vascular access 
Various studies have showed an important influence of patient variables on choice and 
outcome of VA. Age and diabetes mellitus negatively influence fistula maturation and 
increase the risk of AVF failure.(74)  
A very recent systematic review of the literature showed a tendency towards increased risk 
for deep vein thrombosis and a decreased risk for catheter occlusion with PICC.(75) An 
anatomical region at high risk for thrombosis is the antecubital fossa. Elbow veins represent 
a valuable source for the creation of a VA for HD, especially in obese patients, elderly 
patients, diabetics and patients affected by peripheral artery disease.(76) Such veins should 
be preserved (see Recommendation 14, Chapter V).(43) 
Women usually have smaller vessels than men, which may result in poorer maturation and 
lower long-term patencies. Some studies do show that females need more access revisions 
and the creation of more AVGs (56, 77-82), while others, including a meta-analysis, could not 
prove any significant differences in vessel diameters and the chance on maturation between 
man and woman.(49, 83) 
Diabetes mellitus and arteriosclerosis are the most important causes for renal failure and HD 
treatment and can have a negative influence on successful use of the VA.(79) Other 
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variables that influence fistula use are: peripheral arterial occlusive disease (PAOD), race 
and obesity.(84) 
Patients using calcium channel blockers, aspirin and ACE inhibitors, have a better patency of 
AVFs and AVGs.(85) 
 
3.3.2. Secondary option for vascular access 
When there are no options to create an autogenous AVF, an arteriovenous graft fistula with 
the implantation of synthetic (ePTFE; polyurethane; nanograft = electrospun ePTFE graft) or 
biologic material (ovine graft/ Omniflow®) can be created. ePTFE is frequently used as an 
AVG with reasonable short-term patencies but long-term patencies are hampered by 
thrombotic occlusions, due to stenoses caused by progressive intimal proliferation. One and 
two-year primary patencies vary between 40 to 50% and 20 to 30%, respectively. The 
secondary patency varies from 70 to 90% (at one year) and 50 to 70% (at 2 yrs.). Multiple 
interventions to prevent and treat thrombosis are required, to achieve these patencies.(86-
90) 
Elderly patients may benefit from the use of AVGs, because of a high primary failure of 
autogenous AVFs in these patients.(91)  An important consideration for AVG use (in 
particular “early stick grafts”) might be the avoidance of CVCs with their inherent high 
infection risk, in particular when (sub)acute HD treatment is necessary and AVF 
creation/maturation is problematic. 
 
3.3.3. Lower extremity vascular access  
The indications for lower extremity VA are bilateral COVD or inability to create access in the 
upper extremity. Primary options are autogenous greater saphenous (92) and femoral vein 
transpositions (FVT) (93), and prosthetic graft implantation. Thigh accesses have acceptable 
patencies with as disadvantage the risk on ischemia and infection.(94)  
In a meta-analysis the results of femoral vein and AVGs are described. The one year primary 
and secondary patency was 83 and 48% and 93 and 69%, for FV and grafts respectively. 
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Access loss due to infection was primarily seen in AVGs (18% vs. 1,6%; P<0,05). Ischemia 
occurred more in AVFs compared to lower extremity AVGs (21% vs. 7,1%, P<0,05).(95) 
Recently, the outcome of 70 FV accesses was published with good results but a 18% 
incidence of critical ischemia, for which revisional surgery was indicated.(96) 
   
3.3.4. Indications for a permanent catheter for vascular access 
Temporary CVCs are frequently used for acute HD or as bridging access during fistula 
maturation and complications. Permanent tunneled CVCs may be indicated in patients with 
severe access-induced ischemia, cardiac failure or limited life expectancy. Patients with 
peritoneal dialysis (PD) peritonitis or waiting for a planned living-related renal transplant can 
also be dialyzed through a CVC for a limited time period.  
The primary location for a CVC is the right internal jugular vein with subsequently the left 
jugular, femoral and subclavian vein as alternative insertion locations. Femoral and 
subclavian vein CVCs should only be used for short time periods, because of risk of infection 
and COVD. 
Recently, HD via  a CVC has increased in the USA, Canada and Europe, with a significantly 
higher risk of morbidity and mortality due to infectious complications in comparison to the use 
of AVFs and AVGs (Fig. 4).(97, 98)  
The reason of increased CVC use is the inability to create functioning AFVs because of poor 
vessel quality in the elderly, comorbid population. 
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Fig. 4.  Survival (%) of patients with PD versus HD-CVC and HD-AVF/AVG.(98) 
 
 
Recommendation 1 
Referring chronic kidney disease patients to the nephrologist and/or surgeon for 
preparing vascular access should be considered when they reach stage 4 of chronic 
kidney disease (GFR < 30 ml/min per 1.73 m2), especially in cases of rapidly progressing 
nephropathy. Class I, Level C, Ref. (43, 99) 
Recommendation 2 
A permanent vascular access should be created 3 to 6 months before the expected start 
of hemodialysis treatment. Class I, Level B, Ref. (40, 42-44, 99) 
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Recommendation 3 
An autogenous arteriovenous fistula is recommended as the primary option for vascular 
access. Class I, Level B Ref. (37, 38) 
Recommendation 4 
The preferred vascular access is a radial-cephalic arteriovenous fistula. Class I, Level A 
Ref. (37, 39, 50, 52)  
Recommendation 5 
The non-dominant extremity is preferred for vascular access creation when vessel 
suitability is sufficient. Class IIa Level C Ref. (37, 50, 52) 
Recommendation 6 
A  lower extremity vascular access is  advised only when upper extremity access is 
impossible. Class IIa, Level B, Ref. (93, 95, 96)  
Recommendation 7 
Permanent central venous catheters should be considered when the creation of 
arteriovenous fistulas or grafts is  impossible or in patients with limited life expectancy. 
Class IIa, Level B, Ref. (97, 98) 
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CHAPTER IV 
Preoperative imaging 
4.1. Preoperative assessment 
Besides a detailed preoperative history and physical examination, non-invasive ultrasound 
imaging plays an important role in VA selection. Preoperative duplex ultrasonography (DUS) 
enhances the success of creation and the outcome of autogenous AVFs.(100) In a 
randomized trial, a primary failure rate of 25% without pre-operative DUS was observed in 
comparison with a failure rate of 6% with DUS.(101) Ultrasound venous mapping allows a 
precise evaluation of the depth of vascular structures(102) and detects VA sites that may be 
missed by clinical examination alone.  
Especially in patients where physical tests suggest impaired arterial inflow, DUS assessment 
can measure arterial diameters and flow as well as revealing stenotic segments.(103)  
In addition, DUS identifies patients with inadequate vessels in specific access locations. In a 
study of 211 consecutive patients DUS found that 50% of them had an inadequate arterial 
inflow for a distal RCAVF creation.(104) 
DUS provides helpful information before AVF construction such as internal vessel diameters 
and internal venous lesions.(105) Currently, a minimal internal diameter of 1.6 mm for 
arteries and 2.0 mm for veins is recommended preoperatively before RCAVF-creation and 
4.0 mm for AVG-implantation.(43) Furthermore DUS provides important information fo the 
planning of potential future AVF superficialization. 
DSA is helpful in only a small group of selected patients with significant peripheral vascular 
disease and suspected proximal arterial stenosis, where the preoperative endovascular 
approach allows identification and treatment in one procedure. However, the risk of potential 
contrast-induced nephropathy must be carefully considered if iodinated contrast is 
used.(106)  
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Contrast enhanced MR angiography (CE-MRA) is now contraindicated, since Gadolinium 
use is associated with the potential risk of a nephrogenic systemic fibrosis, especially in 
patients with severely impaired renal function.(107) However, CE-MRA enabled accurate 
pre-operative detection of upper extremity arterial and venous stenosis and occlusions.(108, 
109) Promising initial data for the pre-operative visualization of arterial and venous vascular 
structures by non-contrast MRA are available.(110)  
In patients with a history of previous CVCs additional preoperative imaging of the central 
veins may be beneficial, e.g. by venography.(43) 
 
4.2. Imaging methods for vascular access surveillance and maintenance 
4.2.1. Duplex ultrasound 
Duplex ultrasonography (DUS) as non-invasive procedure is the first line imaging method in 
patients with suspected VA dysfunction.(43, 111, 112) However the diagnostic quality of DUS 
depends strongly on the experience of the examiner (113-115) and provides no angiographic 
map for the guidance of further therapy.(116) DUS locates and quantifies stenosis, allows 
flow measurements and detects thrombotic occlusions (117-121) but evaluation of the central 
veins may be limited.(112) 
DUS is a cost-effective technique for the evaluation of VA maturation, surveillance and 
complications.(122-124) If CVOD cannot be reliably excluded by DUS, additional imaging 
methods (e.g. DSA) will be necessary. Surveillance by DUS is reported to prolong AVG 
survival.(125) Only a few studies are available on DUS as an interventional diagnostic tool 
Recommendation 8 
Preoperative non-invasive ultrasonography of upper extremity arteries and veins should 
be performed in all patients. Class IIa, Level B, Ref. (100-102) 
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for ultrasound-guided PTA of failing or non-maturing VA, which may be particularly indicated 
in patients with iodine contrast allergy or with residual kidney function.(126, 127) 
Although VA infection is primarily diagnosed clinically(128) DUS can supplement information 
of extent of infected perivascular tissue and associated thrombosis.  
 
 
4.2.2. Computed tomography 
Multi-slice computed tomography requires the use of iodinated contrast and radiation and 
should therefore only be used if no equivalent technique is available. However, compared to 
DSA CTA is a less-invasive technique that provides important information for further 
treatment (surgery or PTA) and is less expensive than purely diagnostic DSA.(130) CTA is a 
reproducible and reliable technique for the detection of ≥ 50% stenosis or occlusion in 
dysfunctional AVF (131) and showed excellent correlation in stenosis detection compared to 
DSA.(132) CTA allows the evaluation of the vascular tree in failing VA before treatment 
(132), especially if supplemented by 3D image reconstructions.(133) 
Concerning forearm AVF, CTA provides a good VA visualization with moderate sensitivity 
and high specificity for the detection of flow-limiting stenosis.(134) For the detection of CVOD 
the sensitivity of CTA is dependent on the applied examination protocols. In suspected 
CVOD CTA should be considered only when ultrasonography or DSA are inconclusive, e.g. 
for the evaluation of the central veins and visualization of the vascular tree.(135)   
 
 
Recommendation 9 
Duplex ultrasound  is recommended as first line imaging modality in suspected vascular 
access dysfunction. Class I, Level A, Ref. (43, 111-115, 129) 
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4.2.3. Magnetic resonance imaging (MRI) 
Gadolinium may cause nephrogenic systemic fibrosis (NSF) in patients with advanced 
impairment of renal function under HD. Therefore CE-MRA should be used only after 
carefully weighing the risks and benefits of alternative imaging studies.(107) 
Even in the era before NSF had been recognized, CE-MRA had not replaced 
ultrasonography or DSA for preoperative evaluation, but was believed to be appropriate in 
selected cases.(108, 136) It allows non-invasive examination of the arterial and venous 
system.(137, 138) Due to the absence of MR-guided VA interventions, CE-MRA is currently 
used as a purely non-invasive diagnostic tool and potential treatment must be performed by 
additional percutaneous intervention or surgery.(139)  
In comparison with DSA in complex AVF, fewer complications and side-effects were 
observed by the use of CE-MRA.(140)   
In another CE-MRA study, a sensitivity of 100% and a specificity of 94% were observed for 
the arterial and venous trees.(141) In addition, CE-MRA showed high sensitivity, specificity 
and positive and negative predictive values in the detection of stenosed vessel segments of 
dysfunctional AVF and AFG.(137) Non-contrast-enhanced MRA is an evolving technology 
that has been proposed to avoid the risk of NSF. Preoperative mapping and postoperative 
evaluation of the VA have shown promising results in the prediction of failure.(110, 142) To 
the knowledge of the authors, there are no data for the non-contrast MR evaluation of VA 
dysfunction so far.  
 
Recommendation 10 
Computed tomographic angiography should be considered  in patients with inconclusive 
ultrasonography results. Class IIa, Level C, Ref.  (132-135) 
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4.2.4. Digital Subtraction Angiography (DSA) 
In patients with VA dysfunction pure diagnostic DSA without subsequent intervention is not 
advised.(112) In selected cases, DSA may be used in pre-operative vein mapping, e.g. when 
central stenosis or occlusion is suspected or for the surveillance of CVOD, since venography 
is superior to DUS in the detection of CVOD.(117) In addition, DSA offers the opportunity to 
identify and treat central lesions during the same procedure.(143) During endovascular 
treatment and after surgery, DSA is performed to detect inflow, intra-access and outflow 
stenoses as well as residual stenoses or remaining clots(144) and to reveal CVOD.(143)  
 
Iodinated contrast agents can cause further deterioration of residual renal function. 
Nevertheless, DSA with dilute iodinated contrast can be performed relatively safely even in 
patients with end stage kidney disease.(106) However, CO2 angiography is an effective 
alternative, without the risk of further impairment of renal function. CO2 angiography has a 
sensitivity of 97% and a specificity of 85% in the evaluation of upper limb and central vein 
stenosis in comparison with conventional venography.(145) Due to the acceptable results of 
CO2 angiography and the potential risk of NSF gadolinium enhanced DSA(146) is no longer 
indicated. 
 
 Recommendation 11 
Contrast enhanced MRA is not recommended in patients with end stage renal disease, 
because of the potential risk of Gadolinium associated nephrogenic systemic fibrosis. 
Class III, Level C, Ref. (107) 
 Recommendation 12 
 In vascular access dysfunction digital subtraction angiography should be performed only 
for patients with expected subsequent interventions. Class I, Level C.(112) 
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Chapter V 
 
Creation of vascular access 
 
 
5.1. Technical aspects 
5.1.1. Venous preservation 
It is essential to preserve the veins of the forearm in patients who are at risk of CKD as they 
may require HD in the future.(39, 147) Patients and their carers should be instructed to avoid 
intravenous cannulae and where possible venipunctures in the cephalic or antecubital veins 
of either arm. If an intravenous cannula is unavoidable, it should preferably be inserted into 
the veins on the dorsum of the hand to avoid thrombophlebitis of the forearm and upper arm 
veins. The number of available veins for further access is also maximized by a policy of 
performing an AVF at the most distal site available.  
 
5.1.2. Arm exercises  
Arm exercises have been shown to improve arterial and venous diameters and resting blood 
flow in the upper limb in comparison with the opposite rested arm in patients with renal 
failure.(148) Whilst this is likely to be beneficial, it is not yet known whether preoperative arm 
exercise improves AVF patency or maturation (although postoperative exercise with a 
tourniquet has been shown to increase maturation(149) as discussed in Chapter VI). 
 
5.1.3. Preoperative or perioperative hydration 
Recommendation 13 
In patients undergoing or likely to require hemodialysis, intravenous cannulae and 
venipuncture of the cephalic veins and the antecubital veins may be harmful and should 
not be performed. Class III Level C, Ref (35, 36, 39, 147) 
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Hypotension is a known adverse factor in fistula survival(150) and may also cause early 
thrombosis. Rehydration with plasma expanders during access creation improved primary 
patency of AVFs in a randomized study of patients with borderline vessels.(151)  
Recommendation 14 
Patients should be adequately hydrated before or during vascular access creation. Class I, 
Level B, Ref (150, 151) 
 
5.1.4. Prophylactic antibiotics 
There is little evidence concerning the use of prophylactic antibiotics and the creation of VA. 
However, several randomized trials have shown that preoperative broad–spectrum antibiotic 
administration reduces the incidence of wound or graft infection in other vascular surgical 
procedures by approximately 70%.(152) In a small randomized trial cefemandole significantly 
reduced infection after AVG insertion.(153)  Another randomized trial showed that a single 
750mg preoperative dose of intravenous vancomycin significantly reduced the rate of 
infection in AVGs from 6% to 1%.(154) 
Whilst the incidence of wound infection is greater in the lower limb than the arm, a broad 
spectrum antibiotic with activity against staphylococci, such as a cephalosporin, 
amoxycillin/clavulanic acid or a glycopeptide, is recommended preoperatively for all VA 
operations to cover any other focus of infection in the patient, especially in diabetics or if a 
prosthetic graft is to be used. When the local prevalence of methicillin-resistant 
staphylococcus aureus (MRSA) is significant or the patient is a known MRSA carrier, a 
parenteral glycopeptide such as vancomycin or teicoplanin should be considered. In known 
carriers of other multiresistant organisms such as extended-spectrum beta-lactamase 
producing organisms (ESBL) an appropriate antibiotic, such as a carbapenem, should be 
considered according to the bacterial sensitivities.  
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Recommendation 15 
Broad spectrum antibiotics should be given prior to insertion of an arteriovenous graft  
including prophylaxis for staphylococcus aureus. In carriers or in units with a high incidence of 
methicillin resistant staphylococcus aureus cover should be considered. Class I, Level A, Ref 
(152-155)  
 
Recommendation 16 
Broad spectrum antibiotics should also be considered prior to other vascular access surgical 
procedures including arteriovenous fistula construction, especially in the lower limb. Class IIb, 
Level C, Ref (155) 
 
5.1.5. Preoperative antiplatelet agents 
Evidence concerning the use of antiplatelet agents is incomplete. As discussed more fully in 
a later section, three meta-analyses have favored antiplatelet agents to reduce VA 
thrombosis, but the few existing trials have differed in both the drugs and the mode of 
administration and whether they were given to patients with AVFs or grafts. Moreover, in 
most trials the antiplatelet agents were only administered postoperatively.(156-158) Amongst 
the 19 trials cited in the most recent meta-analysis(158) there were only three trials in which 
antiplatelets were administered consistently before surgery: In one trial aspirin caused a 
significant reduction in perioperative fistula thrombosis(159), in the second clopidogrel was 
associated with a significant reduction in primary failure of AVFs although maturation was 
unaffected(160) but in the third the 35% reduction in primary fistula failure with ticlopidine 
administration failed to reach significance.(161) Despite the heterogeneity of these trials, it 
would seem advisable to give aspirin or another antiplatelet agent preoperatively and 
continue postoperatively in an attempt to reduce access thrombosis.  
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5.1.6. Preoperative physical examination 
Prior to surgery the upper limb pulses and superficial veins should be examined clinically by 
an experienced clinician with and without a venous tourniquet in a warm room in order to 
ensure maximum vasodilatation. The patient should also be examined for signs of venous 
hypertension in the limb such as prominent and tortuous collateral veins around the shoulder 
and upper limb edema. The site of any CVC or pacemaker should be noted.(162) The 
chosen site for the fistula should be marked with a permanent marking pen.  
Recommendation 17 
Patients should be examined prior to surgery with a tourniquet in a warm room and 
the proposed site of an arteriovenous fistula should be marked preoperatively. Class 
I, Level C, Ref(162) 
 
5.1.7. Anesthesia 
The majority of AVFs and many AFGs in the forearm or in the antecubital fossa can easily be 
performed under local-regional anesthesia such as lidocaine or bupivacaine initiating a 
sympathetic blockage and leading to dilation with higher perioperative access flows and 
thereby probably better early results.(163). Regional anesthesia such as axillary or brachial 
block takes more time and usually requires the services of an experienced anesthetist but 
has the advantage of causing significant vasodilatation(164, 165), which some surgeons find 
helpful and increase the proportion of distal AVFs in their hands.(166-168)  In one 
randomized trial, stellate ganglion block significantly increased fistula flow, increased early 
patency and reduced maturation time.(169) More extensive access procedures such as 
basilic vein transposition, brachio-axillary grafts or lower limb access usually require either 
regional blockade or general anesthesia.  
Whilst regional blockade may have advantages, there is no evidence to suggest whether the 
mode of anesthesia influences subsequent patency and, in one non-randomized study, 
regional anesthesia and general anesthesia resulted in similar early patencies of brachio-
cephalic and brachio-basilic AVFs.(170)  
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Recommendation 18 
Local or regional anaesthesia should be considered as first choice for upper limb vascular 
access surgical procedures. Class IIa, Level C, Ref (163-168) 
 
5.1.8. Microsurgery and tourniquet use 
Whereas duplex studies have suggested that AVF patency is poor if the internal arterial 
diameter is less than 1.6-2mm and the venous diameter is less than 2mm(171), excellent 
patencies have been obtained for AVF creation using smaller vessels in both adults and 
children using microsurgery and a tourniquet.(172, 173) 
 
5.1.9. Perioperative anticoagulation 
Perioperative anticoagulation with systemic heparin is widely used in vascular surgery to 
prevent intravascular thrombosis during clamping of the vessels. In two randomized trials, 
systemic heparinization (5000 IU intravenously) did not affect subsequent AVF patency but 
increased the incidence of postoperative hemorrhage.(174, 175) In contrast, a third 
randomized trial found systemic heparin improved early patency without increasing 
complications.(176) Following a recent meta-analysis of these three trials it was concluded 
systemic heparin had no effect on patency but significantly increased postoperative 
hemorrhage and therefore should be avoided.(171) Nevertheless, units employing 
tourniquets report no increase in bleeding with systemic heparinization.(172) Local instillation 
of heparinized saline or Ringer’s solution into the vessels or AVG after clamping is the usual 
practice in most units. 
 
5.1.10. Arteriovenous fistula configuration 
For AVFs an end to side (vein to artery) configuration is preferred as it allows easier 
approximation of the vein and artery and avoids the risk of distal venous hypertension 
without affecting patency.(177) For RCAVFs an end to end anastomosis has been advised 
by some to prevent steal syndrome(178) but the incidence of steal in distal AVFs is very low 
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and in the rare occasions where it does occur it can easily be treated by ligation of the distal 
radial artery under local anesthetic provided that the ulnar artery is patent.(179, 180) 
Moreover, the radial artery usually remains patent after thrombosis of the access and 
provides the blood supply to the hand. 
 
5.1.11. Surgical techniques 
It is generally agreed that an AVF should be performed at the most distal site possible, 
provided the vessels are adequate in order to preserve as many vessels as possible (see 
Chapter III).(39, 181) Whilst proximal AVFs have been shown to have a lower initial failure 
rate and better patency than distal AVFs, as would be expected from larger vessels(182, 
183), they have a greater risk of steal(184), may be more difficult to cannulate and are less 
comfortable for the patient. 
Whilst the non-dominant arm is usually preferred, if a pacemaker or CVC is present the 
contralateral side is preferred because of the risk of venous hypertension and possible 
reduced fistula patency.(185) However, when contralateral access is impossible, 
preoperative central venous imaging is advised to confirm free venous flow prior to surgery. 
Lower limb access is the last option as it has a greater infection risk(95), is less convenient 
and less comfortable for the patient. 
Recommendation 19 
In adults when the inner arterial diameter is less than 1.6mm and/or the venous diameter 
is less than 2.0mm an alternative site for access should be found unless the surgeon is 
expert in use of microsurgery under tourniquet. Class IIa, Level B, Ref (171, 186) 
 
 
Recommendation 20 
If there is an indwelling central venous catheter or pacemaker the vascular access should 
be created in the opposite arm because of the risk of central venous stenosis. Class I, 
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Level C, Ref (185) 
 
The first choice for an access is either a snuffbox or RCAVF at the wrist which have similar 
patency in selected patients.(55, 187) A RCAVF may be created at any level in the forearm if 
the wrist vessels are inadequate or thrombosed but, if this is not possible, a BCAVF would 
usually be the next choice. In a meta-analysis of fistula patency RCAVFs had poorer patency 
in the elderly suggesting that a BCAVF might be preferred in such patients(91) but 
subsequent large series have failed to show any patency difference(188, 189) and excellent 
results have been reported for RCAVFs in the elderly in several units.(55, 190) Thus, which 
VA should be performed in the elderly will be determined by patient characteristics and 
physician or surgeon preference.  
Several configurations of BCAVF are possible(39) using the cephalic vein, the confluence of 
the cephalic and basilic veins or the deep perforating vein but there is no evidence that one  
configuration has better patency. The “extension” procedure, which replaces the  
anastomosis to the brachial artery with one to the radial artery 2cm from the origin, is 
technically more demanding but may have a lower risk of steal.(191) There is a 12% 
incidence of a high brachial bifurcation so that the ulnar and radial arteries are both present 
in the cubital fossa. (192) The larger of the two arteries should be used for the anastomosis,  
but, nevertheless, the overall patency may be less than that of standard BCAVFs.(193) 
An ulno-basilic AVF is also an option although the patency is poorer than for RCAVFs.(194) 
Various transposition AVFs are also possible in the forearm (eg ulno-cephalic or radio-
basilic).(195)  
When the veins of both forearms are exhausted, a basilic vein transposition AVF (BVT) is 
usually preferred to a forearm loop graft or a brachio-axillary graft because of its better 
patency. (72, 196-199) and lower infection rate .(200, 201) Whether, this should be 
performed in one stage or two stages is not settled: Three non-randomized studies (202-204) 
and one small randomized study (204, 205)have had conflicting results in terms of patency 
but in one study complication rates were less with a two-stage procedure. In case of small 
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basilic vein diameters two-stage operations may be advantageous to enhance maturation. A 
meta-analysis of 1509 patients showed clearly the preference for creating BBAVF instead of 
AVGs. Pooled secondary patencies were 67% vs 88% for AVGs and BBAVFs, respectively. 
The number of reinterventions was significantly higher in patients with AVGs (1.32 versus 
0.54 per patient/year).(197) However, any advantage of the two stages must be balanced 
against the 6 week delay between operations as well as the extra cost and inconvenience for 
the patient. BVT using endoscopic basilic vein harvest has been described and reported to 
reduce hospital stay without compromising patency in a non-randomized study.(206) When 
the basilic vein is inadequate, the brachial veins or venae commitantes can be used but the 
patency was poorer in some studies.(207-210) Satisfactory results with transposed 
saphenous or femoral vein in the arm has been described in small series but there are no 
studies directly comparing them with AVGs.(211, 212)  
When autogenous options in the arms have been exhausted, AVGs in various configurations 
such as forearm loops and brachio-axillary grafts increase the possibilities in the upper limb. 
 
Recommendation 21 
 When the upper arm cephalic vein is unavailable, a basilic vein transposition 
arteriovenous fistula should be considered in preference to an arteriovenous graft 
because of its improved patency and the reduced risk of infection. Class IIa, Level B, 
Ref (72, 196, 198-201) 
 
Lower limb access is reserved for patients with no remaining options in the arms as it is less 
comfortable for the patient and has a greater risk of steal and infection(95, 213) (see chapter 
III) Femoral vein transpositions are preferred over AVGs in the thigh because of better 
primary patency and lower infection rates (see Chapter III).(95, 101, 204) However, 
ischaemia was much more frequent  for femoral vein transpositions (95) but it was  
eliminated in a small series by avoiding them in patients with reduced ABI  (<0.85) and by 
tapering the vein at the anastomosis to reduce its diameter to 4.5 - 5mm.(93) There is little 
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evidence on the use of saphenous vein thigh loops and, whilst these have been generally 
regarded as having poor patency(95), a recent series of 56 saphenous vein transpositions in 
the thigh reported an acceptable primary patency of 44% at 59 months.(92) When prosthetic 
access is necessary in the thigh, there appears to be no significant difference in infection 
rates or patency between mid and upper thigh AV loops.(95, 214)  
Recommendation 22 
When lower limb vascular access is necessary a femoral vein transposition should be 
considered in preference to an arteriovenous graft. Class IIa, Level B, Ref (95, 214) 
 
5.1.12. Choice of graft 
Both synthetic and biological grafts are available and have been used for VA. In general, 
synthetic grafts have been generally preferred because of lower cost and anxieties about 
long term degeneration in biological grafts, although the latter have a greater resistance to 
infection and may be preferred in contaminated fields.(215)  
Expanded PTFE (ePTFE) grafts are the most widely used. There is some evidence from 
randomized studies that primary patency is better for grafts with an expansion at the venous 
end (216, 217) and non-randomized studies suggesting that heparin-bonded grafts may also 
have better patency.(218) One randomized study has also shown reduced thrombosis with a 
vein cuff at the venous end of a ePTFE graft although the improvement  in primary patency 
failed to reach statistical significance(219) There is no evidence that patency is affected by 
carbon coating, or by external or internal support although the latter may prevent kinking. 
Most surgeons use 6mm grafts although there is no evidence to support this over other 
diameters. Stepped or tapered grafts have no proven advantage despite hopes that they 
might reduce steal whilst preserving patency. Most prosthetic grafts can be used after 1-2 
weeks although newer multilayer ePTFE grafts are self-sealing and can be safely needled 
within 1-2days(220, 221), which can avoid the use of CVCs in some patients.(222) A 
polyurethane graft also may be used within 1-2 days of insertion and has been reported to 
have similar patency to BVT and ePTFE(223, 224) but had an increased risk of infection than 
 
 
54 
 
ePTFE in one non randomized study.(213, 224) A removable plastic sheath prevents 
stretching during tunneling, thereby reducing perigraft seroma caused by “sweating” and 
improved patency in one non-randomized study (‘Slider’ graft).(225) A biosynthetic graft 
consisting of a collagen-polyester composite gave acceptable results in one small 
observational study(226) but had significantly poorer primary patency than brachio-basilic 
AVFs in a small randomized study.(196) 
Because there are no comprehensive randomized studies comparing several grafts no  
definite recommendations can be made concerning which graft should be used routinely but 
a self-sealing graft would be advisable for patients with difficult central venous access and 
who require early HD.  
Combining a standard ePTFE graft at the arterial end with a CVC inserted percutaneously 
(“HeRO” graft) may be a useful alternative to a central venous line in patients with 
inadequate upper limb veins(227, 228) although whether it is preferable to a lower limb 
access is uncertain (see chapter VIII).  
Biological grafts such as bovine carotid artery or bovine mesenteric vein, which have been 
rendered immunologically inert, have been used extensively in some units(215) and have 
compared well with prosthetic grafts in one small randomized study(229) and a further non-
randomized study(230) but their relatively high cost and fears of long term aneurysm 
formation and rupture have limited their usage. Tissue engineered grafts have been used in 
a small number of patients but it is too early to determine whether these have any 
advantages over other grafts.(231) 
 
Recommendation 24 
Recommendation 23 
When an arteriovenous fistula cannot be created, a biological graft should be considered 
in preference to a synthetic graft in the presence of infection. Class IIa, Level C, Ref (215, 
229, 230) 
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The implantation of a self-sealing arteriovenous graft is recommended for patients with 
difficult central venous access and who require early cannulation for hemodialysis. Class I, 
Level C, Ref (222) 
 
5.1.13. Sutures or nitinol anastomotic clips 
Most surgeons use non absorbable sutures such as polypropylene or PTFE but there is 
some evidence from non-randomized studies that the use of non-penetrating nitinol vascular 
clips may improve the subsequent patency of AVFs(232, 233) although this was not 
confirmed by one small randomized study.(234) However, clips are not suitable for use in 
calcified vessels. 
 
5.1.14. Other challenges 
Vessel calcification may limit access options, particularly in diabetic patients, but an AV 
anastomosis can be performed to arteries with mild “egg-shell” calcification either using firm 
bulldog clamps or a tourniquet. Severe calcification makes performing the anastomosis 
difficult and the associated vessel rigidity may compromise maturation. Calcification and 
increased arterial wall thickness have been shown to significantly increase the primary failure 
rate of forearm AVFs(105) and calcification may also be a marker of poor prognosis.(235) 
Obese patients present difficulties in visualizing the veins so that preoperative DUS scanning 
is invaluable. When the vein is located deeper than 0.6cm from the skin surface it may be 
difficult to cannulate which is a possible cause of reduced patency(236) and either elevation 
or transposition either as a primary or secondary procedure may facilitate cannulation with 
patency rates similar to those of non-obese patients.(237-240) Liposuction over a guard has 
also been used successfully to elevate the vein draining an AVF to facilitate needling.(241, 
242) 
 
5.2. Perioperative assessment 
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Whatever form of AVF or AVG is employed, at the end of the operation there should be a 
palpable thrill or, at least, an audible bruit overlying the anastomosis or over the vein close to 
the anastomosis. The absence of a bruit has been found to be a good predictor of early AVF 
thrombosis and whilst duplex ultrasound measurements of end diastolic velocity were a 
slightly better predictor the difference in specificity and sensitivity was marginal.(243) If a thrill 
fails to appear after releasing the clamps on the vessels, application of a vasodilator such as 
papaverine may aid vasodilatation but if this is unsuccessful the anastomosis should be 
carefully checked for defects and an embolectomy catheter or a bougie passed. The 
presence of a strong pulse in the vein draining a fistula without a thrill or bruit usually 
indicates a downstream venous stenosis or occlusion. Intraoperative blood flow 
measurements can also identify fistulas at high risk of failure(244-247) but are relatively 
imprecise and probably have little use in day-to-day practice. Before leaving the operating 
room, the hand should be assessed for ischaemia including capillary return and, in the case 
of proximal fistulas, the radial pulse recorded.  
 
5.3. Perioperative complications 
Arteriovenous grafts or fistulas should be evaluated soon after their creation and then 
routinely examined during their lifespan either by means of physical examination to detect 
physical signs that suggest the presence of dysfunction (monitoring) or  by periodic 
evaluation using tests involving special instrumentation (e.g. DUS) (surveillance). Access 
thrombosis, including early thrombosis within the first 30 days after creation, is the most 
frequent complication leading to failure of either autogenous or prosthetic AV access 
procedures.   
Recommendation 25 
After creation of a vascular access there should be a palpable thrill or a bruit in the 
region of the anastomosis. Class I, Level C(248) 
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5.3.1. Hemorrhage 
Hemodialysed patients have an increased bleeding tendency with  abnormal bleeding times 
despite normal coagulation studies and platelet counts.(248) Scheduling access procedures 
on the day between dialyses sessions decreases exposure to the heparin used to prevent 
clotting in the HD circuit. 
Early post-operative hemorrhage may need rapid intervention for hemostasis while 
preserving the access function. Direct digital compression is required followed by surgical 
revision if the bleeding persists. Clinically significant hematomas remaining after the bleeding 
has stopped may require evacuation to reduce the risk of infection or skin necrosis. 
Recommendation 26 
Scheduling elective access procedures on a day between  hemodialysis sessions 
should be considered to decrease the exposure of patients to the heparin used in 
dialysis. Class IIa, Level C, Ref (248) 
 
5.3.2. Postoperative infection 
VA site infection is an important cause of morbidity and mortality in patients on HD. The 
reported incidence of infections affecting the AV access sites ranges  from  0.5-5% per year 
for autologous AVFs to 4-20% for prosthetic AVGs.(248)  Peri-operative infections (within 30 
days of creation) have a low incidence (0.8%) and account for only 6% of all access site 
infections.(155) They result from contamination during the operation and present as 
abscesses and wound infections.  Autologous AVFs infections are usually localized and in 
the absence of abscess, pseudoaneurysm or hemorrhage may respond to appropriate 
antibiotics.(248) Whilst there is no published evidence on the duration of antibiotic therapy, 6 
weeks treatment has been recommended by analogy to the treatment of endocarditis.(249, 
250)  
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In contrast to late infections, early peri-operative synthetic graft infections involve the entire 
graft and total graft excision is required.(155, 248, 251, 252) When necessary, brachial artery 
ligation should be performed and is in most cases well tolerated.(253) 
Patients who exhibit systemic signs of infection, bleeding, pseudoaneurysm or involvement 
of the anastomosis should have their grafts completely removed or the autologous fistulas 
ligated.(253) 
Recommendation 27 
In the absence of hemorrhage or pseudoaneurysm early peri-operative (<30 days) 
autogenous arteriovenous fistula treatment of infection with appropriate antibiotics 
should be considered . Class IIa, Level C, Ref (248) 
 
Recommendation 28 
Early peri-operative (<30 days) arteriovenous graft infection should be treated by total 
graft removal. Class I, Level C, Ref (155, 248, 251-253) 
 
Recommendation 29 
For early autologous arteriovenous fistula infection in the presence of systemic signs, 
bleeding and involvement of the anastomosis, fistula ligation should be performed. Class 
I, Level C, Ref (248) 
 
5.3.3. Non-infected fluid collections 
Seromas are occasional complications of prosthetic AVGs but are rare in AVFs. They may 
result from “sweating” through a ePTFE graft, which can be minimized by the avoidance of 
stretching.(225) The major concern regarding a seroma is whether it represents a low grade 
infection. Needle aspiration may be helpful diagnostically and may be curative. If a seroma 
persists, the access must be abandoned in favor of a new graft. Other seromas may resorb 
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spontaneously but surgical drainage with excision of the cavity wall or even graft 
replacement may be necessary.(248) 
Lymphatic collections usually resolve spontaneously with or without the aid of repeated 
aspiration(248) but persistent lymphorrhea through a sinus carries a risk of infection, 
especially if a graft is involved. Vacuum assisted closure (VAC) devices have been used 
successfully for open wounds following VA procedures(254) and may aid closure if a lymph 
leak causes a significant open wound. However, it is probably unwise to directly apply them 
over vascular anastomoses or the vein draining an AVF as this might result in major 
hemorrhage from anastomotic disruption or erosion of the vessel. 
 
5.3.4. Early onset of vascular access induced limb ischemia (See Chapter VII) 
A wide spectrum of ischemic symptoms may complicate access creation. Four stages with 
similarities to Fontaine’s classification for lower limb ischaemia in peripheral arterial disease 
have been described (see definitions). (255). Clinically significant limb-threatening ischaemia 
with rest pain (stage 3) or tissue loss (stage 4) occurs in 4-9% of proximal (brachial artery) 
access procedures.(248) Usually, the diagnosis of ischaemia can be easily made by the 
absence of a radial pulse, pallor or slow peripheral return of circulation after compression 
with digital pressures of <50 mm Hg and a digit/brachial index of <0.6 .(255) These changes 
are reversed by compression of the fistula. 
Although more than 80% of steal related limb-threatening ischaemia is caused by discordant 
vascular resistance, 20% results from a proximal inflow stenosis. A arteriography may be 
helpful before embarking on surgical correction in equivocal cases.(256) In half of patients 
with steal, limb threatening VAILI develops within month of access creation, often appearing 
immediately after surgery.(257) Patients should be closely observed during the first 24 
postoperative hours following proximal VA creation and close observation is probably 
unnecessary beyond . Monitoring for steal is not recommended beyond the first 
postoperative month in patients with AVGs, while lifelong monitoring should be performed in 
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proximal AVFs as these may present a delayed onset of steal symptoms after maturation 
and late vein dilatation.(258) 
Early onset limb threatening ischaemia should be treated by immediate surgical correction of 
steal. Ligation is the simplest solution, which requires abandonment of the access site but is 
advisable for severe symptoms of early onset and should be performed urgently to prevent 
tissue loss and permanent neurological damage of ischemic monomelic neuropathy 
(IMN).(248) Some authors have suggested the DRIL procedure but this may not be as 
successful in early onset as for late onset steal.(259) 
IMN may also rarely occur in the absence of steal, probably as a result of transient ischaemia 
during surgery. It is characterized by pain with sensory and/or motor deficit an all three major 
nerves in the affected limb out of proportion to any residual ischaemia. It can be confirmed by 
nerve conduction studies. It requires prompt ligation of the access to prevent continued pain 
and may progress to a useless clawed hand. Treatment in the chronic phase is often 
unsatisfactory and relies on analgesics, antidepressants and anticonvulsants. (248)  
Recommendation 30 
For early limb-threatening vascular access induced ischemia and all cases of early ischemic 
monomelic neuropathy in the absence of steal the access should be urgently ligated. Class I, 
Level  C, Ref (248, 259, 260) 
 
 
 
 
 
5.3.5. Early thrombosis 
The most frequent complication in all access types is early thrombosis which is defined as 
occurring within 30 days of access creation.(9) If the access is to be preserved, treatment 
within 7 days is advisable. The longer the intervention is delayed the more likely the 
thrombus is to propagate and become fixed to the vessel wall, making thrombectomy more 
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difficult and less durable because of damage to the endothelium. The thrombus can be 
removed either surgically using a Fogarty balloon catheter or by endovascular means using 
chemical or mechanical thrombolysis, or a combination of these.   Thrombectomy alone is 
insufficient unless the responsible factor is transient, such as an episode of hypotension and 
any treatment of any underlying stenosis is required. 
Early access thrombosis is usually attributed to technical errors during surgery and is best 
treated by surgical revision rather than endovascular intervention.(261) However, in a series 
of 20 early AVG thromboses only one patient was found to have technical problems and 
most grafts thrombosed because of hypotension, hypercoagulable states or previously 
undetected lesions in the proximal draining vein or central veins.(262) 
Endovascular treatment of early postoperative thrombosed grafts with thrombolysis and 
treatment of any underlying stenosis with PTA/stent, has been shown to give good results 
but should be delayed for at least 7 days after the access creation to allow tissue 
incorporation to prevent puncture site bleeding.(262) In another series of 23 early graft 
thrombosis, reported poor outcomes following percutaneous declotting.(263) During surgical 
thrombectomy, intra-operative angiography and either PTA or surgical revision of any 
underlying stenosis should be performed.(262) 
Recommendation 31 
If the access is to be salvaged after early thrombosis thrombectomy should be 
performed as soon as possible, either by surgical or endovascular means. Class I, 
Level C, Ref (261) 
 
Recommendation 32 
Access salvage after thrombosis within 7 days of access creation should be 
accomplished. Class I, Level C, Ref (262) 
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5.4. Postoperative care 
It is wise to keep the patient and the extremity bearing the newly formed AVF warm to 
promote vasodilatation although there is no evidence to support this. The application of 
transdermal glyceryl trinitrate  to RCAVFs during the immediate postoperative period caused 
significant vasodilatation and increased blood flow in a small randomized trial but, to date, 
there is no evidence that this increases patency rates.(264) Patients should be instructed to 
check the function of their new AVF, by palpating the thrill or, in its absence, by auscultation 
of the bruit. They should be advised to report urgently to the VA nurse or medical team if the 
thrill or bruit disappears and must have easy access to urgent medical help in the event of 
bleeding or signs of infection. 
 
5.5. Training of surgeons to perform vascular access 
Increasing AVF creation rates over AVGs is an indisputable priority. Training of VA surgeons 
seems to be the key predictor of whether priority is given to the placement of AVFs rather 
than AVGs. Surgeons who had performed more AVFs and fewer AVGs during training 
subsequently created more AVFs and fewer AVGs during their specialist practice.(47) 
Greater emphasis on VA surgery during training also was associated with higher odds of a 
patient receiving a AVF versus AVG. Surgeons who had created at least 25 AVFs during 
training had a significantly lower rates of AVF failures than those placed by surgeons who 
had created fewer than 25 with a relative risk of 0.66. (47, 265)  
There is conflicting evidence on whether the grade of the operating surgeon affects access 
outcomes. Two retrospective studies have shown that well supervised trainees do as well as 
specialists (266, 267) whilst another retrospective study concluded that trainees produced 
poorer outcomes. (268) The operating surgeon, seems to be a significant determinant for the 
AVF outcome(46), but in a prospective non-randomized study unsupervised vascular 
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trainees performed AVFs equally effectively as consultants(266, 269) so that AVFs can 
provide good training opportunities without detriment to patient care.  
 
Recommendation 33 
 Vascular access training programs must supervise adequate numbers of autologous 
fistulas for each trainee (> 25). Class I Level C, Ref (46-48, 265-270) 
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Chapter VI 
 
Surveillance of vascular access 
 
 
6.1. Access maturation and care 
 
6.1.1. Concept 
When a fistula is created, a continuous flow from the artery to the vein initiates a cascade of 
changes, altering wall structure, shear stress, and rapidly increasing flow during first 24 
hours, achieving most of the increase in flow and vein diameter up to 8 weeks after access 
placement.(123, 181) AVFs are usually not readily usable after creation, but these changes 
lead the fistula to become suitable for cannulation over time, a process known as 
maturation.(249) 
 
A fistula is considered mature when it is thought to be appropriate for cannulation with 
minimal complications, and to deliver the prescribed blood flow throughout the HD 
procedure. It is established by experienced staff physical examination of the VA and/or 
imaging (DUS), before access cannulation, that predicts successful use and flow delivery 
during HD. It should happen preferably after 4-6 weeks of AVF or 2-4 weeks of standard 
AVG creation.(123, 249, 271, 272) 
 
Cannulation should be considered only in mature VA because of the risk of puncture 
complications, VA failure insufficient HD quality. When is the VA cannulated successfully with 
two needles over a period of at least 6 HD sessions during a 30-day period, and delivering 
the prescribed blood flow throughout the HD procedure (at least 350 ml/min)(273), the 
access is finally considered adequate for HD. An VA that is currently being used for VA 
during HD sessions is considered a functional VA. 
 
 
6.1.2. Maturation of arteriovenous fistula? 
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6.1.2.1. Physical assessment and other diagnostic methods 
Maturation can be established by physical examination of both the venous conduit and its 
flow. It is usually assessed by the presence of an adequate venous diameter with or without 
a proximal tourniquet in place (to permit safe landmark recognition and cannulation), a soft 
easily compressible vein, a continuous audible bruit (a low pitched continuous systolic and 
diastolic audible bruit), a palpable thrill near the anastomosis extending along the vein for a 
varying distance, with an adequate length and superficial enough to be punctured with two 
needles.(181, 274) Experienced staff have shown an excellent ability to predict eventual 
fistula maturity. (123, 249) Causes of non-maturation include any factors that may cause 
difficulty in cannulation and flow delivery (thrombosis, arterial or venous stenosis, small 
diameter or deep veins, presence of accessory veins). 
 
Postoperative ultrasound examination between the first 6-8 weeks and  2-4 months(123) 
after fistula creation is helpful in setting maturation. In general, a draining vein diameter of 
less than 4mm and fistula flow of less than 500 mL/min indicates a fistula that is unlikely to 
mature.(123, 271, 272) Some groups recommend the rule of 6’s to define maturation (at least 
6mm of vein diameter and 600 ml/min flow, and less than 6mm vein depth) (249), which is 
probably quite conservative.  
6.1.2.2. Time to maturation  
An access is cannulated when it is considered mature. However, the optimal delay to use VA 
since its creation, whether autologous or prosthetic, is not unanimously agreed. Premature 
needling may predispose to access failure (because of thrombosis or extrinsic compression 
by hematoma following damage to the thin wall of the freshly arterialized vein), and longer 
maturation time (>30 days) appears to be associated with lower risk of AVF failure. (185, 
275, 276) However, early cannulation can reduce the need for a temporary catheter and its 
complications. Furthermore, significant differences between groups and countries have been 
observed: AVFs were first cannulated <1 month after creation in 74% of Japanese facilities, 
50% of European and only 2% of US. (277)  Early cannulations were not associated with 
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increased risk of VA failure, probably also related to smaller needles and lower flows used in 
Japanese facilities. 
This waiting time is feasible only when there is no impending need for the commencement of 
HD, which is frequently not the case. Thus, clinicians may be able to select appropriate 
patients for early fistula cannulation depending on maturation criteria and the time after 
fistula creation, but also based on the need or the risk of complications of other HD methods.  
If AVF maturation has not occurred by 6 weeks, causes of non-maturation should be 
considered and additional investigations should be performed in order to achieve prompt 
diagnosis and treatment.(123, 271, 272, 278) 
Secondary interventions in previously matured fistulas (i.e. proximal reanastomosis, 
thrombectomies or endovascular procedures), or proximal fistulas in patients with previous 
distal matured fistulas, may need no maturation period if the veins are already mature. 
 
 
 
Recommendation 34 
Arteriovenous fistulas should be considered for cannulation after 4-6 weeks of creation; , 
and standard arteriovenous grafts after 2 - 4 weeks. Class IIa, Level B, Ref. (132, 133, 
135, 185, 249, 275-277, 279, 280) 
Recommendation 35 
If an arteriovenous fistula fails to mature by 6 weeks, additional investigations should be 
considered in order to achieve prompt diagnosis and treatment. Class IIa, Level C, Ref. 
(185, 271, 272, 275-277, 279) 
 
Recommendation 36 
Arteriovenous fistula cannulation before 2 weeks should not be considered. Class III, 
Level B, Ref.(185, 275, 277, 279)  
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6.1.3. Time to cannulation of the arteriovenous graft  
Because of its stiffer wall, AVG usually show weaker palpable thrill over the entire graft than 
AVFs.(249) In grafts, maturation is based on the time needed for tissue-to-graft incorporation 
and for tissue swelling to decrease after graft implantation, rather than flow increase over 
time (because the flow is high from the day of surgery with minimal changes over time).(281) 
It is usually defined as 2 to 4 weeks (followed by62% of USA and 61% of European 
facilities).(277) There was no significant difference in the risk of graft failure between those 
cannulated early in comparison to those with later cannulation.(277, 280) If maturation takes 
more time, causes of non-maturation that are unlikely to improve over time should be studied 
(e.g. excessively deep tunneling or graft thrombosis).  
 
Some grafts allow for early cannulation within 24-72 hours without major complications 
(either polyurethane grafts, or multilayer ePTFE grafts allowing self-sealing), avoiding 
catheters in patients that need early HD and that do not have suitable veins for a fistula. 
However, this type of graft confers no additional benefit other than early cannulation(223, 
282) and mid-term patency outcomes are under investigation.(220) 
 
 
6.1.4. Access care 
After access surgery, patients should receive information about wound healing, warning 
signs (infection, symptoms of ischemic steal syndrome, bleeding and other postoperative 
complications), avoiding fistula compression or injuries, and encouraging an exercise 
program.(149, 283, 284)  
Recommendation 37 
Arteriovenous fistula cannulation between 2 and 4 weeks after creation should be 
performed in selected patients under close supervision. Class IIa, Level B, Ref. (185, 275, 
276)  
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Patients should be instructed to check the function of their new AVF (self-examination), by 
palpating the thrill. They should be advised to report urgently to the VA nurse or medical 
team if the thrill disappears and must have easy access to urgent medical help in the event 
of persistent bleeding in spite of manual compression, or signs of infection.(181, 249) 
 
In patients undergoing HD, experienced staff should examine the fistula in each HD session 
(before fluid removal).(249) Patients in pre-dialysis therapy should be taught how to perform 
self-examination, and at a minimum they must be physically examined by experienced staff 
following a systematic approach 4 to 6 weeks postoperatively.(285) 
 
6.1.5. Assessment and treatment of maturation failure  
Non-maturation rates differ between groups, ranging from just under 10% in BCAVFs to up to 
33%, or even more, in RCAFVs(26); women, older patients, distal placements and accesses 
with smaller artery and vein are risk factors for failure to mature.(272, 286, 287) Additional 
investigations such as DUS or angiography are indicated if physical examination by 
experienced staff determines failure to mature after 6 weeks of AVF creation or poor 
prognostic signs (faint or absent thrill, complete access collapse proximally, discontinuous 
bruit, high pitch continuous systolic audible bruit, pulsatile AVF, low diameter or poorly 
defined vein, excessive depth, large accessory/collateral veins).(123, 278, 288) 
Non-matured fistulas frequently have one or more potentially remediable problems, and up to 
80% can be salvaged after surgical or endovascular correction(289, 290), although thereafter 
cumulative survival rates are decreased and require more secondary interventions to 
maintain patency.(291) The most common causes of non-maturation are venous, arterial or 
anastomotic stenosis, competing veins or large patent branches, and excessive depth from 
the skin.(57) According to the cause, open or endovascular repair can be performed, 
although in general no significant differences have been found between to two 
modalities.(290) (see chapter 7: Clinical Outcomes).  
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Problem-specific salvage procedures increase the proportion of fistulas that are mature and 
usable for HD(288), and if a fistula fails to mature, the patient should be referred immediately 
back to the surgeon or the interventionist for prompt evaluation and intervention.(249, 292) 
 
6.2. Measures to improve maturation  
Apart from time to wait after VA creation, pre and intraoperative treatments, or additional 
postoperative surgical or endovascular procedures (i.e. side branch ligation, 
superficialization, treatment of stenotic lesions and others), other postoperative treatments 
can improve fistula maturation and long-term patency: 
 
6.2.1. Exercise  
After AVF creation, vein diameters immediately increase following arm exercise.(283) 
Compared to non-exercise, hand-arm exercise programs cause significant outflow vein 
dilatation and increase VA flow. In two randomized clinical trials structured hand exercise 
programs significantly increased clinical maturation after AVF creation, mainly in distal 
AVs..(149, 283, 293) Therefore  patients should be encouraged to follow a hand-arm 
exercise program after AVF creation. 
 
 
 
6.2.2. Antiplatelets and anticoagulation  
The role of antiplatelet therapy improving VA maturation or suitability for cannulation is 
uncertain: in recent systematic review and meta-analysis, antiplatelet treatment was found to 
significantly reduce by half early AVF thrombosis and loss of patency.(156-158). However, 
Recommendation 38 
Structured  postoperative hand exercise training can increase arteriovenous fistula 
maturation  should be considered  . Class IIa, Level B, Ref. (132, 133, 135, 149, 283, 
284, 293) 
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antiplatelets had no significant effect on AVF  primary patency, AVF maturation and  did not  
improve VA suitability for HD.(157, 294) 
A preventive role of antiplatelet therapy decreasing cardiovascular mortality in ESRD patients 
had been proposed.(295) However, even if antiplatelet treatment has been related to a 
decrease in myocardial infarction (RR 0.87), all-cause mortality, cardiovascular mortality and 
stroke remains similar, and it was related to an increase in major and minor bleeding (RR 
1.33 and 1.49)(157, 158, 294, 296, 297). Thus, the real benefit of antiplatelet treatment in 
improving access suitability or cardiovascular mortality, specifically in ESRD patients who do 
not have clinically evident occlusive cardiovascular disease, is doubtful. 
Dual therapy (aspirin plus clopidogrel) significantly increased the risk of bleeding, suggesting 
that this combination may be hazardous.(298) 
Anticoagulation strategy using LMWH and oral anticoagulants has not been extensively 
evaluated in HD patients. There is only one randomized study using low-dose warfarin for the 
prevention of AVG failure which found of no benefit,(299) while in DOPPS  such treatment 
was associated with worse graft patency rates.(85) Additionally, in a systematic review 
increased bleeding events were associated with warfarin use compared with placebo in 
patients with fistulae or grafts.(156) Regarding LMWH thrombo-prophylaxis, there is only one 
comparative study with historical controls in a pediatric population reporting a decrease in 
early fistulae failure in the treatment group.(300) 
 
Recommendation 39 
Antiplatelet treatment cannot generally be recommended to improve vascular access 
suitability for hemodialysis or avoid overall mortality in end stag renal disease patients. 
Class III, Level A, Ref. (157, 158, 294, 296, 297) 
Recommendation 340 
Long-term anticoagulation should not be used to prolong vascular access patency in 
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6.2.3. Other treatment options  
Calcium channel blockers and angiotensin-converting enzyme inhibitors have been 
associated with improved primary graft and secondary fistula patency respectively in a single 
observational study, but more conclusive data is lacking.(85) 
There are insufficient data available to adequately assess the efficacy of omega-3 fatty acids 
(fish oil) improving access function or maturation.(301, 302) In a randomized controlled trial 
among patients with new VA grafts, daily fish oil ingestion did not decrease the proportion of 
grafts with loss of native patency within 12 months, but it improved graft patency, rate of 
thrombosis, and interventions. (304) Beside,  there is one large ongoing randomized trial 
designed to test whether fish oil plus aspirin can indeed improve the patency of VA. (303) 
Statins have pleiotropic beneficial actions besides lipid lowering. Two non-randomized 
studies report contradictory results regarding their effects on VA patency rates.(304, 305) 
Until recently, there is no direct evidence of an effect of statins on AV fistulae or AV graft 
patency rates. 
As previously described, most recommendations are based on clinical experience, but 
interventions that clearly improve VA maturation and suitability for HD are needed.(158) 
 
6.3. Cannulation 
 
The maintenance of the VA not only depends on the quality of the blood vessels, and the 
surgical technique used, but also on the way in which the VA is cannulated. After creation of 
the initial VA, preferably an autogenous AVF, the correct needling technique has a favorable 
influence on fistula lifespan. Nurses play a pivotal role in the care of VA: they see the patient 
during every HD session, perform cannulation and assess VA function.(43) VA cannulation is 
a basic but essential part of the HD treatment and requires skill from the nurse, or patient if 
self-cannulating. A chronic HD patient needs at least 312 needle insertions per year (6x52). It 
hemodialysis patients. Class III, Level A, Ref. (85, 132, 133, 135, 156, 299, 300) 
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is reasonable to assume that complications caused by cannulation, such as hematoma, 
infection and pseudoaneurysm formation can have great consequences in terms of 
suboptimal HD, the need for extra needle insertions, patient discomfort, interventions and 
even loss of the access.  
Frequent access complications, particularly with AVGs, have led to the development of VA 
monitoring protocols(306) whose goal is to identify access stenosis and enable intervention 
prior to thrombosis; thereby, maximizing access longevity and minimizing morbidity.(249) 
6.3.1. Access care before cannulation 
6.3.1.1. Skin preparation 
Proper  preparation of the access sites using strict aseptic technique can eliminate 
contamination and/or access infection and should be used for all cannulation 
procedures.(249) VA related infections are a leading cause of morbidity and mortality in HD 
patients. AVGs and CVCs are associated with an increased risk of infection when compared 
with AVF.(307) Studies have suggested that the buttonhole cannulation technique is 
associated with an increased risk of access-related infections.(308-311)  
It has been shown that HD patients are more frequent nasal and skin carriers of 
staphylococcus aureus than the general population.(312) For this reason, meticulous skin 
preparation prior to any cannulation is of critical importance.(313)  
To minimize infections, facilities should have a procedural policy for patient access 
preparation.(314) Dialysis nurses should clean the skin with a facility-approved antimicrobial 
preparation. There are several such cleansing solutions available for VA disinfection each 
one requiring a different length of application and time to be effective (314). The dialysis staff 
should wear clean gloves for cannulation.(249)  
Circular cleansing is generally preferred over the east-west technique although there is no 
hard evidence to support this at present.(249)  
 
6.3.1.2. Anaesthetia 
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Pain related to cannulation is a significant concern for some patients. Anaesthetics available 
for needle insertions include topical creams such as those containing both lidocaine 2.5% 
and prilocaine 2.5%, intradermal lidocaine injection, and  coolant sprays which cause 
reduced pain sensation by rapid skin cooling on evaporation. 
It has been shown that depth of anaesthesia with topical anaesthetic creams depends on the 
contact time: In order to reach a maximal depth of 3 mm, the topical anaesthetic cream has 
to remain on the skin for 60 minutes and to reach a depth of 5 mm the cream has to be on 
the skin for 120 minutes.(315) Side effects are rare but include redness/rashes or whitening 
at the site of the application.  
 
6.3.1.3. Precannulation examination 
VA stenosis is the most common cause of access dysfunction. Monitoring by physical 
examination to detect the physical signs of dysfunction, before any cannulation, is of utmost 
importance. Monitoring should consist of a full physical examination on the VA prior to every 
HD session including inspection, palpation and auscultation.(314) Inspection may reveal 
swelling, signs of infection (redness, discharge, oedema), aneurysms, haematoma, the color) 
of the hand and stenosis. Palpation should reveal a characteristic thrill. A change in the 
strength of the pulse over a short segment may indicate a stenosis, while a pulsatile AVF 
indicates the presence of a downstream or distal stenosis. Post-stenotic collapse of the vein 
on elevation of the arm can demonstrate the haemodynamic relevance of a stenosis. The 
access should have a bruit on auscultation which will be high-pitched over a stenosis.(43) 
Monitoring should also include a review of regular routine laboratory, including HD adequacy 
(urea reduction ratio or Kt/V), and difficulties in cannulation or achieving hemostasis after 
needle withdrawal, documented recirculation, and other clinical clues.(316) Observed 
changes over time should be documented and further investigated by means of vascular 
imaging techniques like DUS, DSA or MRA. Physical examination for the detection of 
stenosis has a positive predictive value of 70% to 80% in AVGs and a specificity of 93% in 
AVFs.(278, 317-321) 
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6.3.2. Cannulation techniques 
6.3.2.1. Needle selection 
It is important to choose the appropriate needle according to the desired blood pump speed 
and the available access flow rate in the VA in order to optimize HD efficiency.  
Needle selection is especially critical for the initial cannulation. One method used to select 
the appropriate needle size is a visual and tactile examination. This examination allows the 
person performing the cannulation to determine which needle gauge would be most 
appropriate, based on the size of the vessels of the fistula. If the needle is larger than the 
diameter of the vein with the tourniquet applied, it may cause infiltration with cannulation. The 
needle size should be equal to or smaller than that of the vein (without tourniquet). It is also 
important to match needle gauge to the blood flow rate. For initial cannulation attempts the 
smallest needle available, usually a 17 G, typically is used. If the arterial pressure falls below 
200 to 250 mmHg, and the venous pressure is higher than 250 mmHg, the needle size 
should be increased (i.e., a smaller gauge number should be used). The arterial needle 
should always have a back eye (an oval hole/opening a the back site of the needle) to 
maximize the flow from the access and reduce the need for rotation and flipping the 
needle.(249)  
 
6.3.2.2. Ultrasound-assisted cannulation 
Cannulation-related complications are especially common in patients with a new VA, which 
may result in the use of CVC or single needle HD, especially in native AVFs.(322, 323) 
DUS guided cannulation of fistulas might improve the cannulation rate of more difficult 
fistulas, potentially reduces the time required to commence HD and the number of local 
complications of cannulation but randomised controlled trials of DUS guided cannulation 
versus blind cannulation are needed.(324, 325). Ongoing education and training of the 
dialysis staff towards theoretical knowledge and cannulation skills, especially for cannulation 
of new AVFs is essential.(322) 
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After creation of an AVG most patients experience significant tissue swelling as a result of 
tunnelling so that palpation of the graft is difficult for the cannulator and painful for the 
patient. Therefore, grafts generally should not be cannulated for at least 2 weeks after 
placement and only after the swelling has subsided and palpation along the course of the 
graft can be performed. Early cannulation grafts should, if possible, be left for at least 24 
hours after placement and until after swelling has subsided so that palpation of the course of 
the AVG can be performed.(249) 
 
Three cannulation methods 
There are three methods for cannulation of the VA; the rope-ladder technique (rotation of 
cannulation sites),  the area technique and the buttonhole technique (constant site 
cannulation).  
 
 
6.3.2.3. Rope-ladder technique  
The rope-ladder technique uses the entire length of the cannulation segment for cannulation: 
every HD session, two new puncture sites are created, with approximately 5 cm between the 
tips of the arterial and venous needles, and at least 3 cm from the anastomosis, avoiding the 
previous sites. The rope-ladder technique results in a moderate vessel dilatation over a long 
vein segment.(326)  
The venous needle is placed in the direction of the blood flow (antegrade). Arterial needle 
placement can be antegrade or retrograde (against the direction of the blood flow). The 
direction of the arterial needle will not influence the risk of recirculation as long as the access 
blood flow is greater than the blood pump flow.(249, 327-330) Bevel position and flipping of 
needles is a controversial issue. Both bevel up and bevel down cannulation are acceptable 
until further studies can demonstrate risk/benefits of either technique.(314, 331) 
Based on assessment of the VA, the dialysis nurse chooses the unique angle of insertion for 
the HD needle. Generally, the angle of insertion for AVF is 25 degrees, and for AVG 45 
degrees.(249) Cannulation of AVG is different than AVF; grafts are tougher than autogenous 
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vessels. Cannulation related complications are more often seen in autogenous AVFs.(322) 
The few publications concerning access handling and the outcome of specific cannulation 
techniques advise the rope-ladder technique for the cannulation of AVGs, to avoid AVG 
disintegration and the formation of pseudo-aneurysms.(43, 323) 
 
6.3.2.4. Area technique 
With the area cannulation technique there will be repeated cannulation in the same area of 
the VA. This may lead to aneurysmal dilatation of the puncture areas with subsequent 
stenoses in adjacent regions.(326) Also the overlying skin becomes thinner, which leads to 
longer bleeding times after the needles are removed. This technique is less widely used, and 
is no longer recommended.(332) 
 
6.3.2.5. Buttonhole technique 
Another cannulation technique is the buttonhole (constant-site) technique.(333) The 
buttonhole technique is not used for AVGs.  
The buttonhole technique requires different skills of the dialysis nurse  than the rope-ladder 
technique as the AVF needs to be repeatedly cannulated at exactly the same site, using the 
same insertion angle and the same depth of penetration every time.(333, 334) In 
approximately 6 to10 sessions a tissue tunnel track is formed with sharp needles, enabling 
the subsequent use of blunt  needles for cannulation. Ideally, a single cannulator should 
cannulate the fistula until an established track is created to reduce the risk of track 
malformation. The cannulation sites should be selected carefully in an area without 
aneurysms and with a minimum of 5 cm between the tips of the needles. After a good 
puncture route is established, the fistula can be punctured with dull edged needles, to 
prevent damaging the tissue tunnel and the formation of faulty tracks.(335) Following 
transition to blunt needles, a single cannulator is no longer required. Subsequent cannulators 
should only use blunt needles and must follow the direction and angle of the developed 
track.(336, 337) 
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Observational studies showed several benefits of the buttonhole cannulation with reduced 
complication rates: fewer infiltration rates resulting in a reduced incidence of haematoma 
formation(308, 336, 338), fewer aneurysms(308, 336, 338), improved haemostasis 
times(338, 339) and less pain during cannulation.(334, 340) Various studies have also 
reported that the buttonhole technique contributes to the cannulation ease for self-
cannulating patients(336, 341, 342), which extends the life expectancy of the AVF.(343-345) 
Recently performed randomized trials regarding the potential benefits of the buttonhole 
technique demonstrated also reduction of aneurysms(346) and less hematoma(346, 347), 
but  did not find difference in pain.(346-348)  
Studies have reported an increased risk of infection in patients cannulated with the 
buttonhole technique.(308-311, 336, 337) These infections ranged from minor skin infections 
at the access site to bacteremia sepsis. Inappropriate application of the disinfection protocol 
with incomplete scab removal by nursing staff or self-cannulating patients was highlighted as 
a likely cause of increased infection rates.(308, 311) Staff re-education regarding cleansing 
technique and scab removal resulted in a reduction of infection rates.(310, 349) 
Correct needle placement with approximately 2 mm of the needle exposed, can prevent the 
development of large scab formation in the buttonhole sites.(334) The best demonstrated 
practice, touch cannulation technique(350) decreases the ability of staff members to 
manipulate needles, resulting in better cannulation success. Antimicrobial prophylaxis has 
been studied in patients using the buttonhole technique with favorable results.(349, 351) 
Currently, the available literature does not recommend the routine use of the buttonhole 
method in all AVFs. However, the buttonhole cannulation technique may be especially 
appropriate for patients with a short cannulation segment.  
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Fig. 5: VA cannulation techniques: A: AV graft, B: rope-ladder technique, C: area technique, 
D: buttonhole technique 
 
 
Several studies have highlighted the importance of staff experience on VA outcomes. The 
DOPPS data found that each 20% increase in the number of experienced staff nurses 
(nurses who had worked in HD >3 years) was associated with an 11% reduction in AVF 
failure (RR=0.89; P<0.005) and 8% reduction in AVG failure (RR=0.92;P<0.001). Careful 
consideration of individual AVF and patient characteristics, patient preference and the 
primary cannulator is required when choosing the most appropriate cannulation method. 
Cannulator inexperience may result in access complications regardless of the technique 
adopted.(352) Therefore, successful access cannulation requires a high level of awareness 
and skills of the dialysis nurse, frequent monitoring, and a continued evaluation and 
education of the needling technique.(308) 
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6.3.3. Access care after needle withdrawal 
The technique of needle removal is as important as that of cannulation, to protect the access 
from damage and to facilitate proper hemostasis. The needle should be removed at 
approximately the same angle as it was inserted. After the needle is removed, gentle direct 
pressure should be applied to the needle exit sites of both the skin and graft or vessel wall, 
using a two digit technique over a hemostatic dressing.(43, 353) Pressure to the puncture 
site should not be applied until the needle has been completely removed, to prevent damage 
of the VA.(43, 314) In general, prosthetic grafts require a longer time to achieve hemostasis 
than AVFs. Whilst compressing, it is important to ensure a flow can be felt in the 
access.(353) 
The use of clamps to assist hemostasis should be discouraged. When clamps are used, they 
should only be applied to a mature access with an adequate flow, monitored closely, and 
should be used only if flow can still be palpated in the AVF or AVG while the clamp is in 
place. A dressing should be applied to the cannulation sites using any number of options 
(with or without a hemostatic agent), but should not encircle the limb to avoid constriction of 
blood flow to the access. Prior to the patient leaving the unit, the quality of the bruit and thrill 
should be assessed and documented.  
Difficulties in cannulation or achieving hemostasis after needle withdrawal can be a sign of 
venous outflow stenosis in a patient with normal bleeding times. If prolonged hemostasis is 
ongoing, the anticoagulation should be reassessed, dynamic venous pressure readings 
should be reviewed, and access flow studies performed to rule out stenosis as a cause.(43) 
 
 
Recommendation 41 
Strict aseptic technique should be used for all vascular access cannulations. Class I, 
Level C, Ref. (43, 132, 133, 135, 249, 312) 
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6.4. Access monitoring and surveillance 
 
6.4.1. Concept 
 
VA function and patency are essential for optimal management of HD patients. Low access 
flow and loss of patency limit HD delivery, extend treatment times, and may result in under-
dialysis that leads to increased morbidity and mortality.(354) In long-term AV accesses, 
especially AVG, thrombosis is the leading cause of loss of VA patency and increases health 
care expenditure.(355, 356) VA related complications account for 15% to 20% of 
hospitalizations among patients undergoing HD.(354, 357, 358) 
 
The basic concept for VA monitoring and surveillance is that stenoses develop over variable 
intervals in the great majority of VAs and, if detected and corrected, under-dialysis can be 
minimized or avoided (dialysis dose protection) and the rate of thrombosis can be reduced. 
Whether prospective monitoring and surveillance can prolong access survival currently is 
Recommendation 42 
Physical examination of the vascular access prior to  any cannulation is recommended. 
Class I, Level C, Ref. (43, 278, 316-321) 
Recommendation 43 
In patients with a short cannulation segment the use of the buttonhole technique should 
be considered over other techniques. 
Class IIa, Level C, Ref. (43, 249, 326, 333) 
Recommendation 44 
The rope ladder technique should be used for cannulation of arteriovenous grafts. Class I, 
Level C, Ref. (43, 328) 
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unproven. A number of monitoring and surveillance methods are available: sequential access 
flow, sequential dynamic or static pressures, recirculation measurements, and physical 
examination.(359) 
A multidisciplinary team should be formed at each HD center(270, 360) with a VA team 
coordinator working proactively to ensure the patient is receiving an adequate HD dose by 
maintaining access function and patency. (270, 361) 
 
 
6.4.2. Monitoring 
 
Monitoring is the examination and evaluation of the VA to diagnose access dysfunction using 
physical examination, usually within the HD unit, in order to detect the presence of 
dysfunction and correctable lesions before access loss. 
 
6.4.2.1. Physical examination 
 
Physical examination can be used as a monitoring tool to exclude low flows associated with 
impending fistula and graft failures. There are 3 components to the access examination: 
inspection, palpation, and auscultation.(362, 363) 
A simple inspection can reveal the presence of swelling, ischemic fingers, fingertip wounds 
like paronychia, aneurysms, rich collateral veins. The detection and referral of patients with a 
non-healing crust over the puncture site can save lives. A strong pulse and weak thrill on the 
vein central to the anastomosis indicates a draining vein stenosis. A fistula that does not at 
least partially collapse with arm elevation is likely to have an outflow stenosis. Strictures can 
be palpated and the intensity and character of the bruits can suggest the location of stenosis.  
In AVGs, the direction of flow is easily detected using a simple compression maneuver on 
the middle segment of the graft, the pulsating part indicates the arterial side and the non-
pulsating the venous side, thus avoiding inadvertent recirculation by reverse needle insertion.  
A local intensification of bruit over the graft or the venous anastomosis compared to the 
adjacent segment suggests a stricture or stenosis.(363, 364) 
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Monitoring by physical examination is cost-effective and a proven method to detect access 
abnormalities.(318, 319, 321, 365, 366) Unfortunately, nephrologists and dialysis staff 
generally have limited knowledge of access anatomy and function, and regular physical 
examination of accesses is generally not carried out in HD units. This trend should be 
reversed by emphasizing proper VA training and clinical assessment in HD units.(285, 363, 
367) Clinical monitoring appears to provide equivalent benefit in terms of VA survival in 
comparison to surveillance programs when coupled with preemptive corrective 
intervention.(129, 368) 
 
 
 
6.4.3. Surveillance 
 
Surveillance is the periodic examination and evaluation of the VA by using diagnostic tests 
that may involve special instrumentation to diagnose access dysfunction. It can be done 
during or outside HD sessions, periodically to diagnose access dysfunction, or when 
monitoring indicates access dysfunction. The aim of surveillance is the detection of 
correctable lesions that may necessitate preemptive intervention to prevent access loss. 
Some diagnostic imaging modalities can also be used to treat the cause of the VA 
dysfunction. 
Recommendation 45 
It is recommended to perform vascular access monitoring by flow measurement of 
arteriovenous grafts monthly and arteriovenous fistulas every 3 months. Class I, Level B, 
Ref. (43, 56, 61, 249, 369-371) 
Recommendation 46 
Routine physical examination and clinical assessment is recommended for vascular 
access surveillance and maintenance. Class I, Level B, Ref (285, 318, 319, 321, 363, 
365-367)  
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6.4.3.1. Surveillance during hemodialysis 
6.4.3.1.1. Flow measurement methods 
VA blood flow can be measured indirectly by using indicator dilution techniques, or directly by 
using either DUS or MRA.(147) 
 
6.4.3.1.1.1. Indirect flow measurement 
The ultrasound dilution technique (UDT) is the most well-validated method for indirectly 
measuring access blood flow(372-375).(376, 377) In this technique, an indicator (saline) is 
infused distally into the VA after line reversal. Ultrasonic sensors measure changes in the 
protein concentration producing dilution curves used for the calculation of Qa. Several factors 
have been identified that directly influence the accuracy of the measurements.(375, 378) 
Firstly, thorough mixing of the indicator is required. Secondly, as a result of cardiopulmonary 
recirculation (CPR), the second pass of the indicator will produce errors if it is incorporated 
into the measurement. CPR increases as access blood flow (Qa) increases (CPR = Qa/CO) 
and if incorporated, will cause an underestimation of the true Qa value. Thirdly, the reversal 
of the blood lines that is required to perform the measurement will also influence the access 
blood flow result.  
Fourthly, blood pump flow delivered to the dialyzer (Qb) must be measured accurately as 
readings from the blood pump have been shown to overestimate delivered Qb by 10% to 
20%.(379)  
 
6.4.3.1.1.2. Direct flow measurement 
DUS measures blood flow velocity and in order to determine blood flow, cross-sectional area 
needs to be measured. The estimated flow can be inaccurate due to operator dependent 
determination of the blood velocity, and may be subject to error in estimation of the cross 
sectional area and the Doppler angle.(379-383) Advances in technology have made newly 
designed instruments more accurate and reproducible in measuring flow. (281, 384) The 
most popular method of flow measurement is calculation of the flow in the proximal brachial 
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artery and subtracting the flow in the contralateral brachial artery which is usually between 
40-150 ml per minute.(385) This technique is supported by most DUS machines using 
automated multiplication of the time averaged mean velocity in the cross sectional area. VA 
flow can also be measured by MRA. However, apart from the danger of nephrogenic 
systemic fibrosis/fibrosing dermopathy, as this technique is expensive and cannot be 
performed during HD it is impractical as a screening tool.  
 
 
6.4.3.1.2. Access flow and pressure surveillance 
After their introduction, AVGs suffered recurrent thrombosis due to venous stenosis, 
necessitating frequent intervention. Dynamic and static dialysis venous pressure (VP) 
measurements combined with preemptive PTA yielded large reductions in thrombosis rates 
and replacement of VAs.(386, 387) These reports led the NKF-KDOQI guidelines to 
recommend that grafts and native arteriovenous fistulae undergo routine surveillance for 
stenosis with preemptive correction of the stenosis.(388)  
The rationale for surveillance is based on the hypothesis that progressive stenosis is 
detected before thrombosis and access loss and a corrective procedure such as PTA can 
maintain patency of the VA. Non-randomized or observational studies are biased toward 
finding a treatment benefit.(389) For example, the influence of Qa on the relative risk of 
thrombosis was used to justify surveillance.(370, 390, 391) Although a low Qa is associated 
with an increased risk of thrombosis, this association does not have adequate accuracy in 
predicting thrombosis. In contrast, Qa and VP surveillances were found to be inaccurate 
predictors of graft thrombosis and instead of preventing thrombosis yielded many 
unnecessary intervention procedures.(392-396) Moreover, PTA induces a mechanical 
trauma, accompanying neointimal hyperplasia, risk of stenosis and impaired access survival. 
(397) Surveillance guidelines should consider differences in risk of thrombosis. For example, 
newly constructed grafts have a higher risk for thrombosis than established grafts.(396) 
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Qa and VP surveillance might improve outcomes if measurements are taken more frequently 
neutralizing hemodynamic variation. Using trend analysis to guide referral decisions rather 
than relying on a single measurement could be more efficient.  
Thus, the screening test should take into account the risks associated with each patient, 
such as graft age or previous thrombosis, and should not be based solely upon a single Qa 
measurement.  
A systematic review and meta-analysis of available randomized controlled trials evaluated 
Qa or DUS in AVFs and AFGs. (129) Flow surveillance of AVFs was associated with a 
significantly reduced relative risk of thrombosis, but no significant improvement in AVF 
survival. By contrast, there was no evidence that AVG surveillance by flow or DUS reduced 
thrombosis or improved AVG survival.(129)  
Another systemic review and meta-analysis found that serial surveillance of asymptomatic 
AV access for detection and treatment of stenosis may reduce the risk of thrombosis and 
prolong VA survival more than usual clinical monitoring but these improvements were not 
statistically significant.(368) 
The frustrating outcome of VA surveillance led researchers to suggest that the current 
surveillance paradigm might be false and that perhaps we should be looking for a new 
paradigm.(398) 
Modified recommendations were suggested for using Qa and VP measurements in access 
maintenance emphasizing the importance of physical examination and clinical assessment. 
(399) Qa or VP measurements should be correlated with physical and clinical examination 
but are not appropriate as the sole basis for intervention referrals. AVF Qa <400–500 ml/min 
and AVG Qa <600 ml/min are associated with stenosis, but should be confirmed and 
correlated with clinical findings when making an intervention referral. The decrease in Qa 
should be >33% since smaller decreases might be caused by haemodynamic variation.(400) 
Trend analysis is essential to using static VP/MAP to detect a significant stenosis. The 
traditional threshold should not be the only basis for an intervention referral.(401) 
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6.4.3.1.3. Dialysis efficiency measurements 
6.4.3.1.3.1. Recirculation 
Access recirculation results from the admixture of dialyzed blood with arterial access blood 
without equilibration with the systemic arterial circulation of dialyzed and non-dialyzed blood. 
AVF recirculation has two components, VA recirculation that may occur when the blood 
pump flow is greater than access flow and cardiopulmonary recirculation that results from the 
return of dialyzed blood without full equilibration with all systemic venous return such as in 
patients with cardiac disease.  
Even with ideal sample timing and proper cannulation, laboratory variability in urea-based 
measurement methods will produce variability in calculated recirculation.(402, 403) 
Therefore, individual recirculation values less than 10% by using urea based methods may 
be clinically unimportant. Values greater than 10% by using urea-based recirculation 
measurement methods require investigation. 
Recirculation rate and access function are closely correlated and it can be assumed that 
improvements in recirculation rate and HD efficiency are parallel. Thus the use of 
recirculation rates in evaluation of the indications for and effects of PTA could be expected to 
contribute to an objective assessment method. The immediate recirculation rate is 
determined by using the hematocrit dilution technique.(373, 404) The total rate per HD 
session is reflected by the urea clearance gap. The correlation between Kt/V and immediate 
recirculation rate is not clear and it may be more appropriate to assess recirculation rate and 
HD efficiency of the total recirculation.(405) 
 
 
6.4.3.1.3.2. Urea reduction ratio (URR) and dialysis rate (Kt/V) 
 
The dialysis rate or Kt/V has been suggested as an objective evaluation method for 
AVF.(406-408) However, it is associated with multiple factors in addition to urea clearance, 
including the length of HD and quantity of blood flow (QB) which can affect Kt/V values. It is 
necessary to include the recirculation rate as a factor in functional evaluation of an AVF.(403) 
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Unexplained decreases in delivered dialysis dose, measured by using Kt/V or URR, are 
frequently associated with venous outflow stenoses.(409) However, many other factors 
influence Kt/V and URR, making them less sensitive and less specific for detecting access 
dysfunction. Inadequate delivery of dialysis dose is more likely to occur with a fistula than a 
graft.  
Failure to detect access dysfunction has consequences on morbidity and mortality.(354, 356, 
410) with significant increase in hospitalizations, hospital days and inpatient expenditures. 
(410) 
Thus the diagnosis of inefficient HD by decreased Kt/V or increased recirculation is very 
important and when accompanied with stenosis. Correction of the stenosis will repair dialysis 
dose delivery impairment and may improve patient morbidity and mortality.(410)  
 
 
 
 
 
6.4.3.2. Surveillance outside dialysis sessions 
Recommendation 47 
When access blood flow (Qa) measurements during dialysis indicate the presence of a 
vascular access stenosis, assessment and correction of stenosis should be considered. 
Class IIa, Level B, Ref.(411)  
Recommendation 48 
VP/MAP >0.50 (or derived static VP/MAP >0.55) is not a reliable indicator of stenosis and 
intervention based on this finding is not recommended. Class III, Level B Ref. (401) 
Recommendation 49 
When impairment of hemodialysis efficiency is detected an underlying vascular access 
stenosis should be investigated and, if confirmed, it may be corrected. Class IIa, Level B, 
Ref. (354, 356, 408-410) 
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Surveillance outside HD sessions can be performed using DUS, MRI, CTA or DSA. 
 
6.4.3.2.1. Ultrasound  
DUS is the main imaging modality for VA surveillance. DUS can enhance the understanding 
of the physiology and pathology of every VA. DUS has been described in Chapter IV. 
 
 
 
6.4.3.2.2. Angiography 
Currently, digital subtraction angiography (DSA) is the gold standard for the evaluation of 
access patency. DSA can be and is used in some centers as a primary surveillance method 
when clinical monitoring findings indicates access dysfunction or after DUS examination.  
6.4.3.2.3. MRA (CE-MRA and NCE-MRA) 
CE-MRA has been introduced for the evaluation of failing access fistulas and grafts. But it is 
not recommended in CKD patients due to gadolinium-induced NSF.(412, 413) 
NCE-MRA is an evolving technology that has been proposed to replace CE-MRA while 
avoiding the risk of NSF. The technology and algorithms are constantly improving but the 
instruments are as yet expensive and cannot widely be used.(110, 142) 
 
 
 
Recommendation 50 
Periodic surveillance of arteriovenous fistulas with duplex ultrasound and preemptive 
balloon angioplasty can be useful to reduce the risk of arteriovenous fistula thrombosis. 
Class IIa, Level B, Ref. (129, 368) 
Recommendation 51 
Periodic surveillance of arteriovenous grafts with duplex ultrasound and preemptive 
balloon angioplasty is not recommended to prevent thrombosis or improve arteriovenous 
graft survival. Class III, Level B, Ref. (414),(129, 368) 
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6.5. Nursing organization 
 
 
6.5.1. Introduction 
In the last decades, it has been recognized that nurses play a pivotal role in VA 
management(415, 416) and surveillance.(417) Within Europe organization modalities 
between HD centers vary from country to country.(418, 419) 
The increasing age and co-morbidities of renal patients have resulted in more complex 
VA(420), demanding higher levels of expertise in the VA management. The coordination of 
clinical care pathways increasingly rely on nurses(421) from the early stages of planning(43, 
422, 423) to cannulation and HD itself.(332, 424) Moreover the expansion of home HD(425-
427) has increased the need for patient education and communication skills and remote 
clinical surveillance.(428, 429) 
 
6.5.2. Nursing organization  
Nurses comprise the largest group of health care workers and the way in which they 
organize their work has considerable effects on patient satisfaction, clinical outcomes. There 
is a consensus that involvement of nurses in clinical management generates considerable 
benefits.(430-434)  
6.5.2.1. Nursing models 
Nurses professionally involved in HD care planning and audit improve their experience and 
accountability which increases self- esteem and maintains enthusiasm.(435) Case 
management(436), Primary Nursing(437-440) or similar structured working models(441, 
442), applied to the HD setting, have proved to have positive impact on clinical outcomes as 
well as management performance.(443-445) 
6.5.2.2. Clinical governance  
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Clinical Governance is defined as a framework through which health care organizations are 
accountable for continuous quality improvement  by creating an environment in which 
excellence in clinical care will flourish. Applying this concept to VA management should 
enhance the quality of care, decrease clinical risks and improve the monitoring of clinical 
outcomes for HD patients.(446-449) 
For this reason, many countries have invested in specialist VA nurses role.(450-452) 
6.5.2.3. Vascular access nurse  
VA nurse areas of competence: 
 Developing and implementing protocols for staff support and patient education  
 VA  monitoring implementation 
 VA data collection and audit  
 Infection and adverse outcome monitoring  
 Quality control of VA care 
 central line insertion upon specific training,  
 
The role and responsibilities of the VA Nurse vary from unit to unit. The responsibilities of the 
VA nurse are to the pre-dialysis and out patients service, communication with the VA 
surgeon, coordination of the operation list and the education of patient and staff, but should 
also lay more emphasis on cannulation. The VA nurse role can be stratified into three levels, 
referred to as a VA nurse, VA nurse coordinator(80, 453, 454) or VA nurse manager.(455) 
In larger units the VA nurses work in teams each member having different responsibilities 
and roles within the team.   
In order to provide examples of VA nurse implementation, the following roles could be 
introduced in a progressive manner: 
6.5.2.3.1. Basic role 
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The first step for a VA management strategy within the HD care team is the appointment of a 
VA nurse. The VA nurse should be skilled in VA  needling and improving patient care. 
She/he should be willing to attend continuing education activities  and should be willing to 
organize a continuing education program for nurses within the HD service. Data should be 
collected on fistula/graft rate, adverse events, CVC type, VA infection rate and staff turn-over 
starting as soon as the VA nurse is appointed and kept thereafter as a continuing audit for 
quality control. The VA nurse should have a well-defined job description, which allows 
him/her to have some autonomy, whilst carefully defining the role and relationships with other 
team members. 
6.5.2.3.2. Vascular access nurse coordinator and manager 
These represent possible developments of the basic VA nurse role.(456) A VA nurse 
coordinator is responsible for building up and coordinating the VA team work, nursing activity 
and pathways of care,  patient preparation and education in all settings relating to VA 
implementation, communication with the access surgeon, follow up after surgery, 
organization of the first treatment/cannulation. Other activities are organizing audits, defining 
protocols for CVC and AVF management. He/she should have a central role in the 
multidisciplinary care team. This role requires a full time post in large HD units. The VA 
coordinator as a highly skilled and educated nurse, supporting HD nurses in any difficult 
cannulation or helping with CVC management queries. 
A multidisciplinary approach to VA including a VA nurse coordinator reduces re-
hospitalizations and complications such as VA thrombosis.(270)  This results in extending VA 
life and reduces the rate of  CVC use.(270, 361) 
Large HD services employ VA nurse managers. Their activities are more on the 
administrative and management side and are responsible for data collection and evaluation. 
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6.5.2.4. Future developments  
The progression of nursing VA competence enhance the need to organize specific post 
graduate VA nursing education, which could be a specific module within a Nephrology Nurse 
Post-Basic Education Course or VA Masters Course(457), in conjunction with universities, 
industries, professional and patients associations 
 
 
 
  
Recommendation 52 
The appointment of one or more vascular access nurse coordinators should be 
considered to improve patient care in each hemodialysis service. Class IIa, Level C, Ref 
(361) (453-456) 
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CHAPTER VII 
Late vascular access complications  
 
7.1.  True and false access aneurysms 
 
Generalized vessel enlargement is a normal finding in autogenous VA due to flow-induced 
vascular remodeling. Aneurysms are localized dilatations, whereas  true VA aneurysms 
involve all layers of the vessel wall and false aneurysms have a wall defect.(458) AVF 
aneurysms are frequently caused or accompanied by pre-aneurysm or post-aneurysm 
stenosis.(459, 460) A hemodynamically significant stenosis will lead to pulsation of the distal 
vein and reduced or missing thrill proximally and lead to aneurysmal dilatation.(461-464) 
Segmental aneurysms without a stenosis may be due to repeated needling in the same area. 
Large aneurysms can be complicated by wall-adherent thrombi producing local signs of 
aseptic thrombophlebitis, which can mimic cellulites secondary to bacterial superinfection of 
a thrombus. Rapidly growing aneurysms lead to  necrosis of the overlying skin and the risk of 
spontaneous rupture and bleeding. In contrast to AVFs, AVGs do not dilate but false 
aneurysms may develop after graft destruction from repeated needling or at the 
anastomosis.(465)  
VA aneurysms have been reported in up to 17% in AVFs and false aneurysms in 7% 
AVGs.(343) VA aneurysms are easily detected on clinical inspection but DUS allows 
detection of associated stenoses and wall-adherent thrombi. VA aneurysms with a thin 
overlying skin, skin erosion or bleeding should be urgently evaluated and treated(459) but 
aneurysm diameter per se does not correlate to complications.(460) 
Cannulation should be avoided in the affected area, especially when this has a thin (often 
shiny) overlying skin prone to infection, which is a sign of impending perforation. In cases of 
progression of aneurysm and stenosis, surgery with partial resection of the wall of the 
aneurysm (aneurysmorraphy) and insertion of the resected material as patch along the 
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concomitant stenosis is common.(459, 460) Stepwise resection of the aneurysm wall and 
resizing over a Hegar’s probe helps to form a suitable conduit for future cannulation. Other 
procedures include ligation of the aneurysmal section and bypass or graft interposition. 
Anastomotic venous aneurysms with a post-stenotic lesion are treated by resection of both 
lesions and graft interposition to the vein distally. AVG pseudoaneurysms are treated by 
resection and interposition or bypass. The presence of infection requires exclusion of the 
aneurysmal section and in most cases, complete resection of the graft (see Section VII :2). In 
all cases where surgery can provide optimal inner diameter while preserving cannulation 
sites, PTA should be the second choice. Very little literature exists on the results of surgical 
treatment of aneurysms. In a small series of 44 VA patients aneurysms or pseudoaneurysms 
developed in 26 AVFs and 16 AVGs.(460), primary patency for AVFs was 57% at 12 months 
and 32% after 48 months.(460) AVFs also fared better than AVGs. 
Different types of covered stents have been used in endovascular treatment of VA 
aneurysms and remain an option in selected cases.(461, 466-472)  
 
Recommendation 53 
Surgical revision of vascular access aneurysms is recommended if cannulation sites and 
access diameter can be preserved. Class I, Level C, Ref. (460, 464) 
Recommendation 54 
Surgical revision of pseudoaneurysms in arteriovenous grafts is recommended when the 
aneurysm:  
- limits the availability of cannulation sites or 
- is associated with pain, poor scar formation, spontaneous bleeding and rapid 
expansion. 
Class I, Level B, Ref.(465, 473) 
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7.2. Infection  
 
VA infection is the major type of infection in HD patients and the second most frequent cause 
of death in these patients, only surpassed by cardiovascular disease.(459, 476, 477) Uremia, 
diabetes, multiple comorbidities, CVCs and repeated cannulation of the VA are important risk 
factors.(252) Infections occur most commonly in association with CVCs, followed by AVGs 
and rarely in AVFs.(252) Diagnosis is clinical with local signs such as  redness, warmth, 
tenderness, swelling and purulent discharge or skin erosions or ulcers. However, occult 
infections do occur with fever as the only symptom.  DUS may be used to look for perigraft 
fluids and radiolabeled leucocyte scans are both sensitive and specific. Non-used accesses 
may pose an infectious risk and often not apparent clinically.(128, 252, 478)  
Infections are caused predominantly by gram-positive cocci (Staphylococcus aureus 50-90%, 
S epidermis, Streptococcus viridans, Streptococcus fecalis.(477, 479, 480) Gram-negative 
Recommendation 55 
Stent graft exclusion of vascular access aneurysms can be considered in selected 
patients. Class IIb, Level B, Ref. (462, 473-475) 
Recommendation 56 
Access cannulation through a pseudoaneurysm is not recommended. Class III, Level B, 
Ref. (132, 133, 135, 459, 460) 
Recommendation 57 
Outflow stenosis should be ruled out in symptomatic vascular access aneurysms and 
treated when present. Class I, Level B, Ref. (462, 464, 474, 475)  
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organisms are found in about 33% of infections.(477, 479-481) Total excision is suggested 
for grafts infected with S aureus, while S epidermidis is less virulent and subtotal or partial 
excision can be planned (252). Infection in meticillin-resistant S aureus (MRSA) in 2 studies 
was associated with higher mortality compared to meticillin-susceptible strains of S aureus in 
HD patients.(482, 483) However, no causal relationship between MRSA and VA infections 
has been established.(477) AVG infections have been shown to be higher in HIV positive 
patients (30%) compared to HIV negative (7%) patients. However, no significant increase in 
VA related infections have been observed in HIV positive patients with AVFs and irrespective 
of CD4+ counts.(484, 485) Due to their immune-incompetence, AVGs should therefore be 
avoided in HIV patients. 
Late infections are more frequent (50%) and associated with routine HD.(155, 252)  
In AVFs, rare infections at the AV anastomosis require immediate surgery with resection of 
the infected tissue. More often, infections in AVFs occur at cannulation sites, especially in 
button-hole cannulation with insufficient aseptic technique. Treatment consists of avoiding 
cannulation at that site. In all cases of AVF infection, antibiotic therapy is begun empirically 
with broad-spectrum antibiotics and then narrowed down based on culture results. Infections 
of primary AVFs should be treated for a total of 6 weeks, analogous to subacute bacterial 
endocarditis, however, proper evidence is lacking.(459)  
AVG infection is associated with risk for sepsis and suture-line disruptions with life-
threatening bleeding. (252) In general,  extensive perigraft effusion requires complete graft 
removal while in some late infections, unaffected ingrown graft segments can be saved.(252, 
486) Late AVG infection may be caused by transient bacteremia from a distant site such as 
an infected oral cavity. Antibiotic treatment alone is rarely sufficient and may instead require 
a combination of antibiotics and graft excision. Total graft excision is the most effective way 
to eradicate infection but usually necessitates placement of a CVC and is associated with a 
significant amount of tissue destruction when removing established infected grafts.(252, 486) 
(487). Subtotal excision refers to removal of the graft leaving only a small stump on the 
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arterial side to be closed. This approach avoids extensive dissection of the artery and risk for 
nerve damage. If the infection is localized to a segment of the graft and ultrasound shows no 
perigraft fluid along the rest of the graft, partial excision of the graft can be performed (470) 
and temporary CVCs avoided. 
Outcomes regarding infection are best with total graft removal (1.6% recurrence rate), less in 
subtotal excision (19%) and 29% in after partial excision.(252, 488-492) The literature 
diverges on the efficacy of conservative treatment (only antibiotics) and the reason may be 
that some of the patients do not have a manifest infection but simply a reaction to the 
prosthetic material that spontaneously resolves and erroneously interpreted as an infection.  
Lately, reports of conservative treatment of infected AVGs with antibiotics, aggressive 
debridement and vacuum assisted closure have emerged but the experience is far too 
scarce to justify any recommendations.(493) 
 
 
Recommendation 58 
All vascular access infections should be treated with antibiotics to cover gram-positive 
and gram-negative organisms. Further therapy should be guided by culture results. Class 
I, Level B, Ref. (252, 459, 486) 
Recommendation 59 
Total arteriovenous graft excision is recommended in patients with sepsis, clinical signs of 
infection, and perigraft fluid around the whole graft. Class I, Level C, Ref. (252, 486) 
Recommendation 60 
Partial excision of an arteriovenous prosthetic graft may be considered in select cases 
when sections of the graft are well incorporated and appear to be uninfected.. Class IIb, 
Level C, Ref. (470, 489)  
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7.3. Stenosis and recurrent stenosis  
 
Stenosis can occur at any level from the arterial inflow to the venous outflow, often in the 
juxta-anastomotic areas or even within the graft.(494) Pre-emptive treatment of all stenoses 
has not been shown to be of benefit.(317, 495-498) Therefore only stenosis that do have a 
hemodynamic effect (≥70% decrease in lumen area) and associated with decreased flow, 
elevated venous pressures, or an abnormal physical exam (less thrill or pulsatile flow) should 
be treated. The main benefit of preemptive treatment of hemodynamically significant 
stenoses is decreased thrombosis, avoidance of sub-optimal HD and CVCs, and not 
necessarily prolonged life of the access.(495, 497-499) 
 
7.3.1. Inflow arterial stenosis  
Stenoses in the brachial, radial or ulnar artery are more frequent in elderly, in diabetes and in 
hypertension. In addition, stenoses often develop at the arteriovenous or arteriograft junction. 
In a prospective multicenter study it could be demonstrated that about 30% of referrals for 
stenosis intervention were due to either stenosis in the native artery or at the anastomosis 
site.(499) In another study 12.5% of dysfunctional AVFs and AVGs were due to inflow 
stenosis and in 77% endovascular treatment was successful.(500) 
PTA is a safe and effective technique with a low rate of reintervention.(499) In case of elastic 
recoil, rapidly recurrent stenosis, or residual stenosis >30% after PTA the implantation of a 
stent is recommended.(459) Open options for treatment of stenoses in the native arteries 
include bypass and endarterectomy but are seldom performed. No randomized studies have 
been performed between open and endovascular surgery. 
 
7.3.2. Juxta-anastomotic stenosis 
For hemodynamic reasons, stenosis often develops in the juxta-anastomotic area around 
either the arteriovenous or arterio-graft anastomosis and the first few centimeters (2-5 cm) 
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into the vein/graft.(494)  
Traditionally open surgery with creation of a new proximal anastomosis or interposition with a 
short ePTFE graft, has been the preferred method in forearm AVFs, (501) although PTA is 
an alternative.(502, 503) It has been demonstrated that PTA can be used as the primary 
approach for juxta-anastomotic stenosis.(504) However recurrent stenosis rate is higher than 
after surgery and in those patients where early recurrence occurs, a surgical revision is 
indicated. If surgical revision is expected to shorten the usable length of the AVF for 
cannulation PTA is justified as the primary tool.  
7.3.3. Venous outflow stenosis 
Reduced VA flow, long bleeding times and elevated venous pressure suggests the presence 
of a venous outflow stenosis often where the peripheral vein enters the deeper system. PTA 
is the first treatment option in the outflow veins (cephalic/basilic), especially when the lesion 
is short (<2 cm). For long-segment stenoses (>2cm), treatment is controversial, including 
PTA or surgery either by graft interposition or vein transposition. Grafts should be reserved 
for patients with exhausted peripheral veins whilst fistula preserving procedures such as 
PTA or patch angioplasty should be favored over graft extensions to central venous 
segments.  
Venous outflow stenoses may be resistant to PTA and require high-pressure balloons or  
cutting balloons.(505) Stents should be considered if repeated PTA fail. Clinical trials 
comparing stenting versus PTA did not show statistical significant differences in patency. 
(506) (507) (508)  Stents used in previous RCTs may have been inferior to more recent used 
devices especially when nitinol stents were used.(509-511) The use of covered stent to treat 
AV access stenosis has recently gained consensus since they may decrease the incidence 
of restenosis by interposing an inert layer to separate the thrombogenic vascular wall from 
the blood flow and impede the migration of smooth muscle cells.(512) Covered stents mimic 
open surgical revision of a graft, preventing elastic recoil and avoiding trans-stent growth of 
neointimal tissue. Recently, a multicenter, randomized, controlled trial found better patency 
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rates for covered stents vs. simple PTA for the treatment of stenosis at the venous graft 
anastomosis(513) with 51% primary patency at 6 months for covered stents compared to 
23% for PTA(P < 0.001). However, thrombosis was not prevented in the covered stent group 
and although not statistically significant, the rate of access thrombosis was higher in this 
group (covered stents 33% vs. PTA 21%; p<0.10). Moreover, the 6 months primary assisted 
and secondary patency were not statistically different between the two.(513) Concerns 
remain about costs, and on the real value in preventing graft thrombosis.(514) Thus the use 
of covered stents to treat AVG venous anastomosis stenosis is reserved for complicated 
cases. The consensus is that for stenting venous anastomosis and venous stenosis, covered 
stents may be superior to bare stents. 
 
7.3.4. Cephalic arch stenosis 
The cephalic vein forms part of the outflow for RCAVF and is the sole outflow for BCAVF. 
The cephalic arch is prone to the development of hemodynamically significant stenosis (494, 
509)related to the  perpendicular junction to the deeper veins. Stenosis in this region is 
common and is usually treated with PTA.(494) The cephalic arch is the most frequent 
location for stenosis of upper arm dysfunctional AVFs, comprising 30% to 55% of all upper 
arm access stenosis sites.(515) It responds poorly to PTA, with a 6-month primary patency 
rate of 42% (459), which is below the 50% unassisted patency rate recommended for 
intervention after access stenosis. When the result of PTA is poor or caused vein rupture, or 
if there was early restenosis (<3months),  covered stents can be used.  (515, 516) Because 
of the problem of restenosis after stenting in the cephalic arch, covered stents have been 
suggested as an alternative in early recurrent cephalic arch stenosis after PTA. 545, 546, (517) 
A randomized clinical study on the outcome of 25 consecutive patients with recurrent 
cephalic arch stenosis has shown the following:(517) Angiography at 3 months demonstrated 
restenosis rates of 70% in the bare stent group and only 18% in the covered stent group. 
Life-table analysis at 3 and 6 months showed that primary patency was 82% in the covered 
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stent group and 39% in the bare stent group. One-year primary patency was 32% in the 
covered stent group and 0% in the bare stent group. It was concluded that the use of 
covered stents for recurrent cephalic arch stenosis significantly improved short-term 
restenosis rates and long-term patency compared with the use of bare stents. The major 
drawback of covered stents in the cephalic arch is possible occlusion of the axillary vein that 
may prevent further access in the ipsilateral arm, but the rate of this complication is 
unknown. Therefore, until long term results are published the use of stentgrafts can only be 
recommended when it is considered unavoidable by an endovascular specialist. The role of 
DEBs is currently being examined and may offer an alternative to stents in VA.(518, 519)   
Since the outflow anastomosis can be considered as an experimental model for intimal 
hyperplasia, future research direction may clarify whether DEBs may offer an alternative to 
stents in VA. 
As an alternative to endovascular therapy, open surgical revision for cephalic arch stenosis 
has been described and involves diverting the blood flow to other patent veins for example  
the axillary vein with a primary patency of 60% at 1 year.(520-522)  However, such 
procedures might jeopardize the creation of a future basilic vein fistula. Furthermore, it has 
been  shown that previous endovascular treatment of the cephalic arch decreases the 
patency of open surgical revision.(523) 
 
Recommendation 61 
Balloon angioplasty is recommended as primary treatment for inflow arterial stenosis of 
any vascular access. Class I, Level B, Ref. (499, 500) 
Recommendation 62 
Surgical proximal relocation of the vascular access anastomosis is recommended in 
juxta-anastomotic stenosis in the forearm.  Class I, Level B, Ref. (501) 
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7.4. Thrombosis 
Thrombosis often presents as the final complication after a period of VA dysfunction and is 
mainly due to progressive stenosis in the access or in the outflow. Treatment needs to be 
started as soon as possible to prevent organization of the thrombus and prevents endothelial 
damage in the vein. Early thrombus removal allows immediate use without the need for a 
CVC.  
7.4.1. Treatment of arteriovenous fistula thrombosis  
In AVFs, thrombosis usually begins at a stenosis site or needle site and propagates until a 
side branch that is open. For example in RCAVFs, open side branches drain the cephalic 
vein even when the anastomosis is thrombosed. However in a transposed basilic vein fistula 
with no side branches, the entire vein is thrombosed. Early thrombus removal is more urgent 
in AVFs compared to AVGs because of endothelial damage and phlebitis may preclude 
further use of the access. Furthermore, the thrombus organization is more pronounced in 
native vessels.(524) The duration and site of AVF thrombosis as well as the type of access 
are important determinants of treatment outcome. Originally the management was 
exclusively surgical thrombectomy. Later, in the 1980s percutaneous management has been 
proposed by thrombolysis first, in combination with mechanical thrombectomy later. A review 
Recommendation 63 
Balloon angioplasty is recommended for the treatment of venous outflow stenosis. Class 
I, Level C, Ref. (508) 
Recommendation 64 
Balloon angioplasty should be considered for the treatment of cephalic arch stenosis. 
Class IIa, Level B, Ref. (517) 
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of comparative and noncomparative studies of percutaneous thrombectomy vs. surgical 
thrombectomy for treatment of AVF thrombosis reveals conflicting results and no definitive 
preference. In a systematic literature review in 2009 36 studies on endovascular and surgical 
intervention for thrombosis of AVFs were identified.(525) To date, no randomized studies 
comparing the 2 alternatives have been published. In forearm fistulas, thrombectomy plus 
simple reanastomosis of the vein to the artery proximally had a better 1year secondary 
patency rate of 70-90%, compared to 44-89% after endovascular therapy.(525) 
Thrombolysis or thrombectomy alone are not sufficient to restore long-term patency, since a 
flow-limiting stenosis is present in more than 85%of the cases.(526) Identification and 
treatment of these underlying lesions are crucial to optimize long term result. The 
combination of thrombolysis with PTA allows a good immediate result ranging from 88 to 
99%, but re-occlusion is frequent.  
Endovascular technique includes pharmacological thrombolysis (urokinase or tissue 
plasminogen activator), pharmaco-mechanical thrombectomy (lytic agent combined with 
mechanical thrombus maceration), mechanical thrombectomy (thrombosuction, 
hydrodynamic catheter or catheter with a rotational tool) or a combination of these.(527-529) 
Pharmacological thrombolysis can result in adequate thrombus resolution but it is time 
consuming and associated with a higher risk of bleeding and incidence of pulmonary 
embolization in comparison to surgery. Mechanical thrombectomy devices significantly 
reduce procedure time. Independently from the type of device used for pharmaco-
mechanical or mechanical thrombectomy, the technical success rates are better in AVGs 
compared to AVFs (99 vs 93%), although early re-thrombosis is more common in AVG.(530) 
A direct comparison among three different mechanical devices for endovascular 
recanalization of AV access thrombosis revealed that the result of PTA in the treatment of 
underlying stenoses was the only predictive value for graft patency.(531) 
 
7.4.2. Treatment of arteriovenous graft thrombosis 
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Unlike AVF thrombosis, treatment of AVG thrombosis is not as urgent but should be 
managed without jeopardizing access function for the next HD session. Early declotting 
allows for immediate use of the access without the need for a CVC. Old thrombi (> 5 days) 
are often fixed to the vessel wall beyond the venous anastomosis, making surgical extraction 
more difficult than interventional treatment. Surgical thrombectomy is performed with a 
thrombectomy catheter purposely designed for use in grafts. Intra- operative  angiography 
can visualize the central venous outflow as well as the graft in order to exclude residual 
thrombi and identify and treat the cause of thrombosis which should be an integral part of 
any surgical or interventional declotting procedure. 
In a meta-analysis(261) and in a systematic review in 2009(525) the conclusion was that 
surgical thrombectomy was superior to endovascular therapy. A recent randomized study did 
not show any significant difference between surgical thrombectomy and endovascular 
treatment. (532)  
 
 
Recommendation 65 
Thrombosed vascular access should be treated as soon as possible to restore access 
function for hemodialysis. Class I, Level B, Ref. (525) 
Recommendation 66 
Late thrombosis  of vascular accesses can be treated either by surgery or by 
endovascular means depending on the center’s expertise. Class IIa, Level B, Ref. (525) 
Recommendation 67 
Treatment of vascular access  thrombosis should include perioperative diagnosis and 
treatment of any associated stenosis. Class I, Level C, Ref. (526, 530, 531) 
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7.5.  Central venous occlusive disease  
Central venous occlusive disease (CVOD) is a common finding with an incidence of 2-
40%.(143, 496, 533-535) It may be asymptomatic but can cause upper extremity, facial or 
breast swelling, increased venous outflow resistance, post-cannulation bleeding, fistula 
aneurysms, and may lead to loss of the access, and preclude future VA creation in the 
ipsilateral limb.(143, 533) These lesions associated with prior CVC use, increased blood flow 
and by extrinsic compression (see 7.5.1.).(143, 535, 536) Twelve to thirteen percent of 
patients with HD access have symptomatic CVOD that may require some form of 
intervention and 25-50% of all subclavian CVCs are associated with subsequent CVOD 
whereas lower rates have been reported for jugular vein catheters.(534, 537, 538) Clinical 
suspicion of the diagnosis should be confirmed by either fistulography or CTA. DUS is 
generally less useful since visualization of central venous outflow may be difficult but can be 
of help using defined criteria.(539, 540) 
There is no ideal treatment for this problem. Since surgery requires sufficient expertise and is 
associated with increased morbidity PTA with its low morbidity and good short term patency 
has become the accepted treatment for symptomatic CVOD (459). Poor long-term patency 
rates after PTA are due to elastic recoil (541) or recurrent intimal hyperplasia and repeated 
interventions are often necessary. Bare metal stents have not demonstrated an advantage in 
long-term patency over PTA and are not recommended in mobile axillary vein segments and 
subclavian segments underneath the clavicle.(535, 536, 542, 543) 
In view of the reported superiority of covered stents compared with bare stents for recurrent 
cephalic arch stenosis these have been used for cases of symptomatic CVOD (517, 544, 
545), however the possible disadvantage of covering major venous confluences must be 
considered.(546, 547) 
Despite a significant morbidity, surgical revision should be considered in patients with CVOD 
and failed endovascular attempts.(548-551) Various procedures include bypassing the 
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central occlusion (axillary or brachial vein to jugular vein; axillary vein to saphenous or iliac 
veins), intrathoracic central venous reconstructions, extra-anatomical venous reconstruction, 
and non-venous HD access (axillary or brachial artery to right atrium bypass). Hybrid 
procedures combining surgical bypass and endovascular recanalization with covered stents 
may also be an option. In addition, high flow fistulas with CVOD may also be treated with 
flow reducing procedures such as fistula vein banding.(552, 553)  
 
7.5.1. Hemodialysis-associated venous thoracic outlet syndrome 
About 10% of central stenosis occurs without previous CVC placement.(554) Extrinsic 
compression of the subclavian vein at the costoclavicular junction is a less common cause of 
venous hypertension or upper extremity swelling in the VA patient, but should be kept in 
mind, when no CVC has been used. The etiology can be compression of the subclavian vein 
between the clavicle, first rib and costoclavicular ligament causing thickening of the vein wall, 
stenosis and thrombosis.(555) Lesions may be asymptomatic until placement of a VA, which 
increased blood flow, arm swelling and/or cannulation problems. 
Diagnosis is obtained by dynamic phlebography with abduction or elevation of the arm. DUS 
may detect subclavian vein compression before VA placement but the vein segment behind 
the clavicle is difficult to visualize.(539) 
Stenoses with this etiology responds poorly to PTA and stents invariably fail.(556) The 
treatment of choice is surgical decompression of the thoracic inlet by first rib resection and 
venolysis.(557) Residual stenosis may require PTA after decompression. Stent placement 
should be avoided. The largest series of patients treated this way, consisted of 12 patients, 8 
of whom achieved patency beyond 8 months.(557) Occlusion of the subclavian vein usually 
require other treatment strategies such as jugular vein turndown (558), extraanatomical 
bypass from the axillary vein to the internal jugular vein (559) or decompression followed by 
subclavian interposition graft (557). 
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7.6. Vascular access induced limb ischemia and high-flow vascular access 
VA induced limb ischemia, often referred to as hand ischemia or 'steal' after primary VA, 
occurs in 5-10% of cases when the brachial artery is used for inflow but in less than 1% of 
RCAVFs. Increase in age and diabetes in the HD population has raised the incidence of 
Recommendation 68 
Persistent arm edema or  development of vein collaterals over the ipsilateral chest region 
more than 2 weeks after creation of a vascular access should be evaluated by 
fistulography or computed tomographic angiography to evaluate ipsilateral central venous 
outflow. Class I, Level B, Ref. (539, 540) 
Recommendation 69 
Symptomatic central venous outflow disease should be treated primarily by balloon 
angioplasty, and repeated interventions when necessary. Class I, Level C, Ref. (535, 536, 
542, 543) 
Recommendation 70 
The use of bare stents is not recommended in the treatment of  central vein stenosis. 
Class III, Level C, Ref. (517, 544, 545) 
Recommendation 71 
Covered stents or repeat balloon angioplasty may be considered if there is significant 
elastic recoil of the vein after balloon angioplasty  or if recurrent stenosis occurs within 
less than 3-months. Class IIb, Level B, Ref. (542, 543, 545) 
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symptomatic peripheral ischemia to the hand.(560) Other causes of access associated 
complications in the lower arm, hand and fingers such as carpal tunnel syndrome, venous 
hypertension and IMN should be considered when clinical symptoms of ischemia are less 
pronounced.(561) Regular monitoring after access placement is mandatory and high-risk 
patients should be carefully evaluated such as elderly and diabetic patients. Clinical 
examination should include pulse palpation, presence of supraclavicular bruits indicating 
proximal arterial stenosis, bilateral blood pressure measurements, and evaluation of the 
hand circulation with and without temporary access occlusion by digital compression.(560) 
Diagnosis can be obtained by DUS to evaluate distal arm and hand circulation and digital 
blood pressure measurement or digital pulse oximetry, preferably with and without temporary 
access occlusion. Surgical or endovascular procedures require information from DSA or 
CTA.(560, 561) An access surgeon should readily evaluate patients with symptoms of VA-
induced ischemia. Non-healing ulcers and emerging digital necrosis should lead to prompt 
intervention and if limb viability is threatened, access ligation may be the only option. In 
cases with milder ischemia, symptoms during exercise or HD or rest pain, the cause of the 
ischemia should be diagnosed and therapy aimed to reduce distal ischemia with maintained 
access function. Flow reducing arterial stenoses proximal to the anastomosis should be 
treated with PTA.(562) High-flow–induced steal with VA-induced ischemia requires reduction 
of outflow diameter to create a significant stenosis (80%) either through banding (563) or by 
a surgical revision to decrease anastomosis diameter or through the creation of a new AV 
anastomosis in the forearm arteries as opposed to the brachial artery (RUDI) (Fig 6a-b).(564-
566) The procedures should include intraoperative flow monitoring to ensure adequate flow 
reduction. (567) In RCAVFs with high-flow, ligation of the proximal (or distal) limb of the 
artery, depending on the cause of the elevated flow may be successful (Fig 6c).(179, 180, 
565, 568) VA-induced ischemia with normal or near normal access flow and significant distal 
vascular disease represent the majority of cases.(255) Several reports support the use of a 
DRIL procedure.(569-572) Here, the AV anastomosis is bridged by a venous bypass and the 
artery ligated distal to the AV anastomosis (Fig 6d). The proximal by-pass anastomosis 
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should be placed at least 10 cm above the access anastomosis to ensure adequate deviation 
of sufficient flow to the distal extremity. In RCAVFs with ischemia, ligation of the distal limb of 
the radial artery may be an alternative (Fig 6e). Intraoperative flow monitoring or DUS may 
be advisable to verify increase in peripheral arterial perfusion.(567, 570) Alternatively, 
improved distal perfusion may also be obtained by a more proximal AV anastomosis (PAVA) 
(Fig 6 f). (573) HD patients with VA flow > 1500ml/min should be monitored regularly by flow 
measurements, echocardiography and clinical signs of CHF evaluated. Progression of 
symptoms, progressive increase in access flow or objective signs of decreased cardiac 
function should be considered for surgical procedures described above. 
 
 
7.7. Neuropathy 
 
Distal nerve function can be acutely impaired after AV access placement in the upper 
extremity using the brachial artery as inflow site.  The most serious condition, ischemic 
Recommendation 72 
In patients with symptomatic vascular access-induced extremity ischemia with arterial 
inflow stenosis balloon angioplasty should be considered. Class IIa, Level C, Ref.(560, 
562) 
Recommendation 73 
Symptomatic access induced extremity ischemia in patients with high-flow access should 
be treated by surgical procedures aimed to reduce access flow under intraoperative flow 
monitoring to ensure optimal flow reduction with maintained access function and 
improved distal perfusion. Class I, Level C, Ref. (564, 565) 
Recommendation 74 
A DRIL procedure should be considered in patients with vascular access induced limb 
ischemia and upper arm access without high-flow. Class IIa, Level C, Ref. (569-572) 
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monomelic neuropathy (IMN), is caused by axonal ischemia in peripheral nerves that can 
lead to severe and nonreversible limb dysfunctions.(561, 574-576) Other causes are 
aggravation of pre-existing uremic or diabetic neuropathy or nerve compression due to 
postoperative soft tissue edema.(577) Prevalence and incidence numbers are unknown and 
case reports prevail . True ischemic neuropathy can affect either nerve although the radial 
nerve seems most susceptible.(578) The underlying etiology appears to be reduced 
collateral flow in vessels to major nerves in the antecubital fossa, most often after brachio-
cephalic AVFs, with subsequent ischemic axonal injury or reversible demyelination 
injuries.(575, 579) Diagnosis of acute ischemic neuropathy after access creation is difficult. It 
should be suspected in patients with diabetes and pre-existing neuropathy, distal arterial 
disease and after creation of upper arm access. The patient generally presents with 
immediate postoperative sensory or motor loss in the distribution of all or one of the three 
major peripheral nerves from motor function compromised to cause wrist drop, sensory 
compromise with paresthesia and numbness or striking pain. Isolated nerve compromise 
should be suspected to be due to soft tissue nerve compression. The peripheral circulation is 
usually satisfactory with a warm hand and even with distal pulses. The condition may mimic 
true VA-induced ischemia, post-operative edema or carpal tunnel syndrome.(561) It should 
be treated with immediate access closure to prevent further neurological deficit.(575, 580, 
581) Despite adequate actions, persistent neurological deficit and extremity malfunction is 
common.  
 
Recommendation 75 
Patients with diabetes or pre-existing neuropathy receiving an upper arm vascular access 
should be monitored post-operatively for signs of ischemic neuropathy. Class I, Level C, 
Ref. (576, 581) 
Recommendation 76 
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7.8. Non-used vascular access 
 
There is neither consensus nor clinical evidence in favor of routine closure of a functioning 
VA following successful kidney transplantation.(582, 583) Reports indicate that most 
accesses remain patent after kidney transplantation.(584, 585) VA closure may be indicated 
in high-risk patients with pre-existing CHF, refractory CHF after transplantation, high-flow 
accesses, other access complications, and for cosmetic reasons.(582, 583) Access ligation 
has been shown to improve cardiac function in kidney transplant recipients (584), but, there 
are few studies reporting follow-up of cardiac function in transplant patients (585-587) and 
improvement of several physiological parameters have been observed both in patients with 
patent access as well as after access closure (585). Non-used AVGs may become infected 
over time, which must be considered in all patients with prior synthetic implants. In a series of 
20 patients with non-used AVGs who presented with fever or sepsis positive blood cultures 
were present in 15 of 20 patients and all were positive on indium scans and had pus around 
the grafts. (128) Interestingly, in the same study 15 of 21 asymptomatic patients with 
abandoned, thrombosed ePTFE grafts had positive indium scans. Subsequent removal of 
the AVG in these patients revealed purulence surrounding the graft in 13 of 15 patients. 
Another study reported that of all graft infections at their center, 23% were in thrombosed 
grafts. (155) 
 
Acute ischemic neuropathy should be treated with immediate vascular access closure to 
prevent further neurological deficit. Class I, Level C, Ref. (575, 580, 581) 
Recommendation 77 
Routine closure of a functioning vascular access after successful kidney transplantation is 
not recommended. Class III, Level C, Ref. (582, 583) 
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Recommendation 78 
Vascular access closure may be indicated in patients with refractory heart failure after 
transplantation. Class IIb, Level C, Ref. (582, 583) 
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CHAPTER VIII 
Complex or tertiary hemodialysis access 
 
There is a subgroup of more challenging patients who will require complex tertiary access.  
The expectations, age and co-morbidities of the HD population are rising as well as the 
number of years for which people are being sustained on HD. There are also a group of 
younger patients who become increasingly sensitized with each failed transplant and thus 
more difficult to re-transplant from both an anatomical as well as immunological perspective.  
The factors that result in repeated renal allograft failure are also those that challenge the VA 
surgeon. These factors include hypotension, thrombophilia and absence of vein in continuity 
with the right atrium. Achieving tertiary VA often requires the access surgeon to be inventive 
using their understanding of the general principles of fistula formation as well as vascular 
anatomy to create an access that may be a unique “one-off”.   
 
8.1. Tertiary vascular access 
8.1.1. Suggested classification of types of tertiary vascular access surgery.     
The most appropriate tertiary access procedure for an individual patient depends on their 
available vessels and the experience of the surgeon. These may be divided into three groups 
of increasing risk and complexity, which should therefore generally be considered in 
sequence:  
Group one - upper limb, chest wall and trans-located autologous vein from the lower limb 
(see Chapter V). 
Recommendation 79 
When standard upper limb vascular access sites have been exhausted complex access 
procedures need to be considered according to the availability of suitable vessels. Class 
IIa, Level C 
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Group two - lower limb. 
Group three - access spanning the diaphragm, and other unusual access procedures 
including upper and lower limb arterio-arterial loops.   
 
8.1.1.1. Group one – Upper limb, chest wall and trans-located autologous vein from 
the lower limb 
Upper limb VA is preferred because of the increased morbidity when the lower limb is used. 
When a functioning upper limb access is jeopardized by central venous stenosis or 
thrombosis venoplasty or recanalization and stenting of a stenosed or occluded outflow vein 
 should be attempted to treat arm swelling and preserve the access. This includes sharp 
needle recanalization of the outflow vein if experienced radiological support is available.(588)  
If recanalization using endovascular techniques fails then the next option could be a bypass 
using a prosthetic conduit onto the ipsilateral axillary/subclavian(589) or jugular vein(590) via 
an infra-clavicular or low neck incision respectively (Fig 7a).  This chest wall surgery uses 
exposures identical to the ipsilateral axillary artery – vein loop(590, 591) and ipsilateral 
axillary artery - jugular vein loop (Fig 7b) as well as the cross-over bypass necklace 
procedures (592, 593) (Fig 7c). Another option for patients with functioning upper limb 
access compromised by major central stenoses is a prosthetic bypass from the axillary vein 
to the saphenous, femoral or iliac vein. The surgical exposures spanning the diaphragm are 
described in section 8.2.1.3.(549) (594). In another  series of eight such cases (550), the 
upper limb access continues to be needled in the arm and the long chest wall conduit serve 
purely to decompress the arm.   
 In a report of 49 patients with only one postoperative death and the remainder all continuing 
to use their upper limb access it was concluded that prosthetic veno-venous bypass is a 
robust solution for patients with occluded central veins.(595)   
 
8.1.1.1.1. Great saphenous vein  and femoral vein translocation 
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The GSV translocated to the upper arm is commonly believed to have  high complication and 
poor maturation rates although acceptable results were reported in a recent small series220. 
Using FV as a conduit in the upper arm has good patency but suffers from  a very high 
complication rate, specifically, of steal because of the caliber mismatch.(596)   
 
8.1.1.1.2. Access to the right atrium 
A recent innovation designed to minimally invasively access the right atrium is the 
Hemodialysis Reliable Outflow (HeRO) device. This provides a subcutaneous coupler 
somewhere in the axilla/upper arm or neck which is at the end of a 5 mm nitinol-reinforced 
silicone catheter that traverses any central venous lesions before entering the right atrium.  
The Coupler can then be attached to a 6-mm expanded polytetrafluoroethylene graft which in 
turn may acts as the AVG once anastomosed to an inflow or simply be joined to an existing 
native AVF in order to salvage or maintain it. 
Published experience includes two multicenter studies of 164 and 409 cases(228, 597) and a 
number of trials comparing the device with other tertiary access procedures(598) and 
tcCVCs,(599)  The 12 month primary and secondary patency rates were reported as 11% 
and 32% respectively. (600) A further series reported figures of 9.1% and 45.5%.(601)  It has 
been used successfully to treat access-induced arm edema. 643 In one study the average 
number of previous access attempts prior to placement of a HeRO catheter was as few as 
two and in addition to poor patency rates. There was a high complication rate with a 
particularly high incidence of steal syndrome (24%, all women). (600) 
 
8.1.1.2. Group Two -  Lower limb  
Lower limb VA is associated with steal (95) and infection(213)reinforcing the importance of 
reconsidering suitability for peritoneal dialysis. This group comprises AVF formation using 
either the great saphenous vein, femoral vein or AVG.  Imaging of the lower limb arteries and 
veins including the ilio-caval veins is important when planning  any lower limb VA as well as 
taking a full vascular history and measuring the ABI to avoid operating on a patient with PAD. 
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Some authors have described lower limb access being created preferentially as a result of 
patient choice.  Reasons given include the facilitation of two-handed self-cannulation, having 
both hands free during HD.(602, 603) The increased risk of sepsis and limb threatening 
ischaemia does not support this practice.   
 
8.1.1.2.1 Great Saphenous Vein 
Once significant lower limb vascular disease has been excluded a few patients may be 
suitable for an autogenous posterior tibial–greater saphenous lower extremity AVF at the 
ankle although data is limited.(604)  
Data for the saphenous vein thigh loop, which was first described in 1969 and where the 
GSV is anastomosed to the superficial femoral artery is also poor.(37, 605, 606)   In a review 
48 patients were reported with 56 sapheno-femoral AVFs.(92)  A loop configuration was 
avoided by anastomosing the GSV to the mid/lower SFA. The cumulative  (ie secondary) 
patency was 65-70% at one year with 5 patients developing pseudoaneurysms.(607) In a 
small series of 8 patients with saphenous thigh loops the fistulas had poor flow and the 
complication rate was high with five haematomas, one thrombosis and two fatal 
hemorrhages.650 These data suggest that the GSV performs poorly as an AVF in the lower 
limb. 
 
Recommendation 80   
The use of great saphenous vein for lower limb vascular access is not recommended due to 
its high incidence of complications.   Class llI, Level C, Ref. (37, 92, 607) 
 
The main choice to be made is between Femoral Vein Transposition (FVT) and a Lower 
Extremity Arteriovenous Graft (LEAVG) bridging the femoral vessels either at groin or thigh 
level (see chapter V).  Any prosthetic material placed into the groin carries a significant risk 
of infection with rates of between 18%(608)  and 37.5%.(213)  In as study 22 LEAVGs in 21 
patients were compared with 60 HeRO devices in 59 patients.(598) This was an 
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observational study with more obese patients receiving the HeRO device.  There were 
almost twice as many interventions required per annum to maintain HeRO patency than 
lower extremity graft patency (2.21 vs 1.17) with no differences in infection rate or mortality at 
6 months.   Obesity however was considered an indication for FVT (93) which suggests that 
a future study is warranted to compare the infective complications of FVT  with the HeRO 
device.  
 
8.1.1.3. Group three – Access spanning the diaphragm, other unusual access and 
prosthetic upper or lower limb arterio-arterial loops. 
 
This small group of patients are subjected to a very disparate and unusual range of 
operations for which no good evidence base exists.  They will by definition be end-stage VA 
patients.   
 
8.1.1.3.1. Axillo-iliac, axillofemoral and axillopopliteal 
Long grafts are described tunneled subcutaneously from the axillary artery to the femoral or 
iliac vein or from the femoral artery to axillary/subclavian vein (Fig 7d).   When deciding 
which pelvic vessels to use, good quality paired arteries and veins should be preserved to 
retain technical feasibility for renal transplantation.  Bypasses from the axillary artery to the 
IVC are described(595)  and the authors have personal experience of creating a left iliac 
artery to IVC access (Fig 7e).   An axillary artery to popliteal vein prosthetic fistula is an 
example of a unique and rare access tailored to a specific patient’s available vessels.(592, 
609) 
 
8.1.1.3.2. Arterial – arterial chest wall and lower limb loops 
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These fistulae warrant consideration for patients without easily accessible venous drainage 
to the right atrium, patients with PAOD who would be at risk of steal and also because there 
is no increase in cardiac demand. 
In a series of 34 prosthetic axillo-axillary loops placed in 32 (Fig 7f)(610)  eleven patients 
were obese, as defined by a body mass index of >30 kg/m2. The secondary patency rate was 
59% at 1 year (median, 18 months) with a one year patient survival of 69%. Infection 
occurred in 15% patients. The 30 % one year mortality demonstrate that this end stage 
access group is highly morbid. Another report with 36 loop grafts placed in 34 patients of 
whom 5 had femoral arterial-arterial leg loops follow up was much longer.(611)  Primary and 
secondary patency at one year was 73% and 96% and at 3 years 54% and 87%, 
respectively. Occlusion of the lower limb arterio-arterio AVFs required immediate 
thrombectomy for limb salvage, whereas thrombosis of the upper limb access did not result 
in limb threatening ischaemia. 
 
Recommendation 81 
End stage dialysis access patients can be reasonably considered for arterial – arterial loop 
grafts as a last resort. The axillary artery – axillary artery chest wall loop should be 
considered before creating a lower limb arterial - arterial loop graft. Class llb, Level C, Ref.  
(610, 611)  
 
There are a number of anecdotal access cases that represent case reports, extreme 
examples of which include the femoro-renal access graft  and access grafts sutured to the 
right atrium via a thoracotomy(612) or sternotomy.  These types of procedure are final 
attempts to gain access in patients who would otherwise perish.  A high peri-operative 
mortality of this major surgery is therefore expected and experienced.   
8.2. Complex central venous catheters 
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Conventional tunneled catheters are discussed in chapter III (3.3.4).  Despite the clear 
evidence that tcCVCs should be avoided by achieving timely native access, there remain a 
significant number of patients who require placement of complex high-risk salvage lines such 
as trans-lumbar, trans-hepatic(260, 613) lines and lines through the parenchyma of a failed 
renal allograft or the native kidney to access the inferior vena cava.(614) The morbidity and 
mortality of complex line insertions and their short term benefit would suggest that they 
should only be used after all other options, including complex grafts and peritoneal dialysis 
have been ruled out.  In this context, peritoneal dialysis catheters can be safely placed under 
local anaesthesia(615-617), may still be possible after previous abdominal surgery (618)  
and can  be used immediately for low volume exchange.(619)   
 
Recommendation 82 
Individuals should not undergo the insertion of a high risk complex hemodialysis line without 
serious consideration of either the placement of a peritoneal dialysis catheter or a tertiary 
vascular access.  Class llI, Level  C, Ref.  (260, 613, 614, 616, 618) 
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Chapter IX 
GAPS in the Evidence  
Robust evidence is still needed in many aspects of the management of VA. Adequate trials 
are lacking. As a consequence most recommendations have been rated evidence of Level B 
or C.  
Future research directions could be defined: 
 Trials on durability of prosthetic grafts and CVCs should be started.  
 A registry on post access creation ischemic neuropathy would be of great value.  
 Patient specific choices for access should be investigated. Do patients with limited life 
expectancy benefit from AVG more than from AVF? 
 Studies evaluating HD techniques should be undertaken: high vs low flow dialysis, 
intensive HD 
 Cannulation hemodynamics and damages to the access through needling 
 Organization of early patient referral and of pre-dialysis care are major subjects for 
research. A policy of venous preservation should be educated and implemented 
 Trials on long-term follow-up and cost/benefit analysis for current available treatment 
techniques 
 Studies on tissue engineered grafts 
 Studies on new anastomotic technologies (laser) 
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